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Primary breast carcinoma is the most common type of cancer among women and 
radiodermatitis a frequent complication of treatment. The study aims were to examine the 
feasibility of measurements of radiodermatitis and gain a better understanding of quality 
of life (QOL) among 40 women with grade 0-III breast carcinoma receiving radiotherapy 
at a community cancer center. 
Study design feasibility, clinician-measured breast length, and multiple 
assessments of breast radiodermatitis were explored in a pilot study. Maximum 
radiodermatitis score significantly correlated with breast length (p =.04), and with the 
following breast areas: upper inner quadrant (p=.04), upper lateral quadrant (p=.02), and 
lower lateral quadrant (p=.02), inframammary fold (p=.001). Clinician-measured breast 
lengths and participant-reported bra cup sizes were discordant estimates of breast size. 
Change in skin-related and global QOL between baseline and at week 5 on 
radiotherapy was measured using the Dermatology Life Quality Index (DLQI) and the 
Quality of Life Instrument-Breast Cancer Patient Version. The relationship between, and 
factors associated with, skin-related and global QOL were examined. In general, skin- 
related and global QOL were highly correlated. Skin-related QOL changed profoundly 
(M=.40, SD=1.19; versus M=3.88, SD=3.55, t(-6.32), p<.001) while global QOL did not 
change (M=296.90, SD=74.18; versus M=292.55, SD=72.23, t(60), p=.55) between 
baseline and five weeks on radiotherapy. 
We initiated the validation of the DLQI when used to measure skin-related QOL in 
breast radiodermatitis. Thirty-one (78%) participants provided narrative feedback on how 
the experience represented by each DLQI item impacted her life. Agreement between 
DLQI ratings and coded narratives ranged from 71% to 98%. Aside from work and study, 
the DLQI subscales demonstrated good internal consistency, α =.84. 
Content analysis was implemented to describe 28 participants’ narrative response to 
an open-ended question about the most important DLQI item. Analysis of 60 narratives led 
to the identification of six themes: perspectives on having radiodermatitis, sensations  
caused by radiodermatitis, knowledge and preparation for radiotherapy, prevention of 
radiodermatitis, emotions induced by skin changes, and physical appearance of the breast 
skin. 
Results suggest radiodermatitis has a significant impact on skin-related QOL; breast 
length measurements and multiple assessments of radiodermatitis may improve breast 
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Statement of the Problem 
 
Breast cancer is the most prevalent cancer among women worldwide (American 
Cancer Society [ACS], 2016). See Figure 1.1. Approximately 1.5 million women 
worldwide were expected to develop breast cancer during 2008 (ACS, 2011). 
Additionally, 246,660 women in the U.S. are expected to develop breast cancer in 
2016 (ACS, 2016). Most of these women will require radiation therapy. 
Although radiotherapy is the standard of care for most breast cancers, it is not 
without significant iatrogenic sequelae that are likely to have a negative effect on patient 
quality of life. Up to 100% of women receiving external beam radiation therapy for breast 
cancer experience grade one or higher radiation dermatitis (Di Franco et al., 2013  [97%]; 
Diggelmann et al., 2010 [80-90% erythema]; Gosselin, Schneider, Plambeck, & Rowe, 
2010 [95%]; Knobf & Sun, 2005 [100%]; López et al., 2002 [91.7% erythema]; Osako et 
al., 2008 [96% conventional, 83% hypofractionated]). Aside from washing the  breast and 
using IMRT, there is no standard clinical guideline for the prevention and treatment of 
radiation dermatitis (Pignol et al., 2008; Roy, Fortin, & Larochelle, 2001).  Clinical trials 
of topical agents to prevent radiation dermatitis have demonstrated  conflicting results. 
While there may be reasons related to the agents themselves that lead  to inconclusive 




efficacy of the agents. This reflects a number of issues in the design of previous studies: 
 
1) Often only one global assessment of breast skin is conducted weekly, 2) Most studies 
of radiation dermatitis do not quantitatively or qualitatively measure the patient’s 
symptom experience, 3) There are no skin-related quality of life instruments 
independently validated for use in radiation dermatitis. As a result, we remain unable to 
effectively assess the usefulness of topical agents that could decrease suffering, prevent 
treatment delays or early termination, and improve quality of life for thousands of breast 
cancer patients. By improving our approach to the assessment of radiation dermatitis and 
quality of life experienced during this toxicity, we may determine the best methods to 
prevent and treat this problem. Potential solutions include using a quality of life 
instrument specifically designed for skin conditions (e.g., the Dermatology Quality of 
Life Index; Basra, Fenech, Gatt, Salak, & Finlay, 2008) to improve assessment of patient 
perception of quality of life during the presence of radiation dermatitis and to expand the 
number of assessments of the breast during radiation therapy from one global assessment 
to seven sites in the radiation treatment field. This may provide increased sensitivity to 
small but clinically significant objective changes in radiation dermatitis during 
intervention studies. 
Radiation dermatitis has a profound impact on quality of life. For example, Haas 
and Moore-Higgs (2010) recount the experience of one patient who commented, “I feel 
like I am on fire, and I am not sure I want to finish treatment” (p. xiii). Yet little is known 
about skin-specific quality of life. As suggested by the quote above, patients experiencing 
severe radiodermatitis may be hesitant to complete treatment. Additionally, skin reactions 




have a significant adverse impact on treatment outcome (Bese, Sut, & Ober, 2005, 2007). 
Studies of the prevention and management of radiation dermatitis have varied in method 





The primary objectives of this research were to examine the efficacy of and pilot 
test measures of skin toxicity to be used in a larger future study and gain a better 
understanding of quality of life among women who are receiving whole breast radiation 
therapy at a community cancer center for grade 0 to III breast carcinoma. 
 
Specific Aim 1 
 
Determine the feasibility of conducting a future longitudinal study and pilot 




To determine the feasibility of recruiting, enrolling, and following women with 









Explore the utility (i.e., usefulness) of clinician-measured breast length (i.e., 
distance between the inframammary fold and nipple) and participant- reported bra cup 









Calculate effect sizes to allow a scientific estimate of the sample size needed for 
the future study. 
 
Specific Aim 2 
 
Initiate the validation process of the Dermatology Life Quality Index (DLQI) 




Measure the agreement between the participant responses to the DLQI items and 
their narrative feedback regarding the impact of constructs represented  by the DLQI 














Estimate the reliability of the DLQI subscales when used in our population of 




Specific Aim 3 
 
Describe the thoughts and experiences of women experiencing radiation 
dermatitis of the breast at a cancer program in a community setting as associated with 
skin-related quality of life. 
 
Specific Aim 4 
 
Investigate the impact of breast radiodermatitis on skin-related and global quality 




Explore the relationship between skin-related and global quality of life among 




Describe the change in skin-specific and global quality of life (QOL) among 
women undergoing external radiation therapy for breast cancer  between baseline and at 
week 5 on radiotherapy. 
 
Organization of the Dissertation 
 
This dissertation is organized into eight chapters. This chapter introduces the 
statement of the problem, specific aims, and research questions. Chapter 2 provides the 
background and significance of the breast radiodermatitis, and skin-related and global 
quality of life. The conceptual model of the study design and methods implemented in  the 
study are explicated in Chapter 3. The next four chapters (i.e., Chapters 4 through 7) are 




results included in Chapter 4 describe a  feasibility and pilot study of breast 
radiodermatitis. Chapter 4 reflects our findings regarding specific aim 1. The results 
presented in Chapter 5 describe the initial  validation of the Dermatology Life Quality 
Index (DLQI). This chapter explores  specific aim 2. The results in Chapter 6 describe 
women’s perceptions of skin-related  quality of life and relate to specific aim 3. The results 
provided in Chapter 7 describe the impact of radiodermatitis on skin-related and global 
quality of life. This chapter relates to specific aim 4. The review of pertinent literature and 
description of methods may overlap between the manuscripts and other chapters in this 
dissertation. A  summary of our study results, limitations experienced, and 
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Figure 1.1. Breast cancer is the most frequently occurring cancer among women worldwide. American Cancer Society. 









BACKGROUND AND SIGNIFICANCE 
Introduction 
 
This purpose of this chapter is three-fold. First, breast cancer and its treatment are 
described. Second, the pertinent literature regarding radiation dermatitis is reviewed. 
Third, global and skin-related quality of life are discussed. 
 
 
Breast Cancer Overview 
 
Breast Cancer Incidence and Mortality 
 
Breast cancer is the most frequently occurring solid tumor and second leading 
cause of cancer death among U.S. women following lung and bronchus (American Cancer 
Society [ACS], 2016). During 2016, approximately 246,660 women and 2,600            
men will develop breast cancer in the United States and another 40,450 women and 440 
men are expected to die of this disease (ACS, 2016). Similar to the U.S., breast cancer is 
the most common site of primary cancer and the leading cause of cancer death among 
women across the globe (ACS, 2011). During 2008, 1,383,500 new cases of breast cancer 





Anatomic Pathology in Breast Cancer 
 
Currently, primary breast cancer is defined as a carcinoma (i.e., malignant cells) 
originating in the breast tissue. Breast cancers are described and classified using a 
number of methods. Some of these descriptors include depth of invasion, hormone and 
other receptor status, histologic type, and anatomic stage. 
Depth of invasion is an indicator of prognosis. “Carcinoma in situ” refers to a 
superficial cancer that remains confined to the cells of the tissue of origin; while 
“invasive” or “infiltrating” refers to a cancer that extends below the basement membrane 
in the cells of a tissue. Cancers that have not become invasive are more easily cured and 
less likely to metastasize. Conversely, invasive cancers are more difficult to cure and 
more likely to metastasize to distant locations. 
Healthy breast tissue has hormone receptors for estrogen and progesterone. In 
nearly two-thirds of breast cancer, the hormone receptors retain their function (College of 
American Pathologists [CAP] & American Society of Clinical Oncology [ASCO], 2010). 
The estrogen receptors allow estrogen to stimulate breast cancer growth. The estrogen 
receptor (i.e., ER) and progesterone receptor (i.e., PR or PgR) status is used to help 
classify breast cancers (Allred et al., 2009) and portends response to hormonal therapy 
and survival. 
Human epidermal growth factor receptor (i.e., HER) is a constituent of normal 
breast tissue. In 20-30% of all breast cancers, a specific type of HER called HER2/neu is 
overexpressed (Yackzan, 2011). Overall, breast tumors that overexpress HER2/neu have 
a poorer prognosis (Wiseman et al., 2005). 




include invasive ductal, invasive lobular, medullary, tubular, mucinous, inflammatory, 
and Paget’s disease. 
Invasive ductal breast carcinoma (IDC) is the most common type and accounts for 
65-85% of all breast cancers (College of American Pathologists [CAP], 2011). Breast 
cancers that cannot be classified as another subtype are known as IDC (Yackzan, 2011). 
IDCs that are well-differentiated are usually ER and PR positive and HER2/neu negative, 
while poorly differentiated IDCs tend to be ER and PR negative and HER2/neu positive 
(Yackzan, 2011). 
Tubular breast carcinomas are a subset of IDC. They have a spiculated (i.e., 
spiked) appearance and are typically found on mammogram among postmenopausal 
women (Yackzan, 2011). Unlike typical IDC, tubular carcinomas do not frequently 
spread to the axillary lymph nodes (Yershulami, Hayes, & Gelmon, 2009). They tend to 
be ER and PR positive, but HER2 negative (Yershulami, Hayes, & Gelmon, 2009). 
Invasive lobular breast (ILC) carcinoma is the second most common form and 
accounts for 10-15% of all breast cancers (CAP & ASCO, 2010). ILCs demonstrate an 
Indian file pattern where the cancer cells form a single file straight line in the breast 
stroma (Yackzan, 2011). Like the IDCs, ILCs that are well-differentiated are typically ER 
and PR positive and HER2/neu negative, while poorly differentiated IDCs are likely to be 
ER and PR negative and HER2/neu positive (Yackzan, 2011). 
Medullary breast cancers (MBCs) tend to occur in younger women with BRCA1 
genetic mutations and grow rapidly (Yackzan, 2011). These cancers tend to appear as 
benign lesions on medical imaging (Yershulami, Hayes, & Gelmon, 2009). MBCs tend to 




MBC requires five criteria: 1) a syncytial growth pattern [i.e., multinucleated mass of 
cytoplasm], 2) a circumscribed border without microinvasion, 3) inflammatory features 
including large to moderate lymphoplasmacytic infiltrate, 4) a nuclear grade that is 
poorly differentiated [i.e., appears vastly different from the original tissue], and 5) a high 
mitotic rate (Rapin et al., 1988; Vincent-Salomen et al., 2007). Although MBCs have 
these very aggressive pathologic features, they have better outcomes than other breast 
cancers with similar aggressive pathologic findings, likely due to increased sensitivity to 
chemotherapy and radiotherapy (Vincent-Salomen et al., 2007). 
Mucinous breast cancers have a palpable mass filled with mucin. The mucin 
creates difficulty in imaging the mass. They tend to be ER, PR, and HER2 positive 
(Yershulami, Hayes, & Gelmon, 2009). Mucinous breast cancers tend to occur in older 
women (Yackson, 2011) in their seventh decade (Yershulami, Hayes, & Gelmon, 2009). 
Inflammatory breast cancer (IBC) originates on the breast skin and accounts for 1- 
5% of all breast cancers (Yackson, 2011). IBC causes the breast skin to become 
erythematous, warm, and tender. These factors can mimic radiation dermatitis. In fact, 
IBC is often misdiagnosed as a benign dermatitis, is rapidly progressing, and has a 
survival rate of only 5% (Robertson, 2010). Over half of all IBCs are ER negative and 
approximately one-third of IBC cases are ER, PR, and HER2 negative (Robertson et al., 
2010). 
Paget disease is a very rare cancer involving the nipple or areola. Paget’s disease 
causes erythema, irritation similar to eczema, ulceration, and crusting of the nipple or 
areola (Yackzan, 2011). Most Paget’s disease breast cancers are ER and PR negative (Fu, 




The “TNM” system is used to stage breast cancer. “T” represents the tumor size 
in centimeters. “N” represents regional lymph node involvement. “M” represents distant 
metastases. Stage 0 refers to noninvasive breast cancers. Stage 0 breast cancers include 
carcinoma in situ and no lymph node or distant site involvement. Stage I includes breast 
cancers with a tumor size of 20 millimeters or less and no or only microscopic invasion 
of the lymph nodes. Stage II includes those breast cancers with a tumor size of 50 
millimeters or greater or the involvement of up to three axillary lymph nodes. Stage III 
includes breast cancers with tumors that may extend to the chest wall or involvement of 
at least four axillary lymph nodes or involvement of the ipsilateral (i.e., same side as 
breast cancer) internal mammary lymph nodes or involvement of the ipsilateral 
supraclavicular lymph nodes (American Joint Commission on Cancer [AJCC], 2010). 
Stage IV refers to breast cancers that have metastasized to distant locations. In 
breast  cancer, these locations typically include the bones, brain, and lung. Radiation 
therapy for stage IV breast cancer provides palliative treatment at the distant site. 
 
Treatment of Breast Cancer 
 
The primary treatment for most breast cancers is surgery (National 
Comprehensive Cancer Network [NCCN], 2015). Surgery typically includes removing 
the tumor and a small margin of healthy tissue (i.e., lumpectomy, segmentectomy) or 
removing the breast (i.e., mastectomy) then performing or forgoing reconstruction. 
Prognostic factors that estimate the likelihood of cancer recurrence and predictive 
factors  that estimate the likelihood of tumor response to treatment are used to determine 
whether systemic therapy is indicated (National Cancer Institute [NCI], 2009). Systemic 




targeted drugs  (NCI, 2009). Chemotherapy alone or with radiotherapy added has shown a 




Radiation therapy is a “local” treatment when used for breast cancer. It is 
administered to specific areas of the breast and sometimes to nearby lymph nodes. 
According to the American Cancer Society, Surveillance and Health Services Research 
(2013), a review of the 2008 National Cancer Database revealed that 51% of women with 
breast cancer in stages I to II and 44% with breast cancer stages III to IV receive some 
form of radiotherapy. The types of radiation therapy most frequently used to treat breast 
cancer are described below. 
 
Conventional Radiation Therapy 
 
A linear accelerator is used to provide conventional external beam radiation 
therapy. The radiation beam travels from the gantry of the linear accelerator to the target 
on the patient’s body. The height and width of the tumor are matched, but healthy tissue 
is also exposed to radiation. The participants of the current study did not receive 
conventional radiotherapy. 
 
3-Dimensional Conformal Radiation Therapy 
 
The beams of radiation used in 3-dimensional conformal radiation treatment are 
shaped to match the tumor. This technique allows better targeting of the tumor with higher 
radiation doses and sparing of healthy tissue. The participants in the present study received 




Intensity Modulated Radiation Therapy (IMRT) 
 
IMRT uses hundreds of small radiation beams to conform to the shape of a tumor. 
 
Each radiation beam is individually controlled by the treatment plan. The shape of the 
beam changes hundreds of times during each treatment to focus on the tumor and to spare 
healthy tissue. IMRT is associated with a decreased, but not completely obviated, 
incidence and duration of radiation dermatitis (Freedman et. al., 2009; Pignol et al.,  
2008). IMRT can be provided by some linear accelerators and all tomotherapy units. 
IMRT was not implemented by the cancer program in the community setting of our study. 
 
 
Accelerated Radiation Therapy 
 
Accelerated radiation therapy is also administered via a linear accelerator using 
external beams. The daily dose is increased, but administered in fewer fractions of 
radiotherapy. Seven participants in the present study received accelerated radiotherapy of 
the whole breast. 
 
Partial Breast Irradiation 
 
Partial breast irradiation treatment focuses on specific areas of the breast such as 
the lumpectomy cavity compared to radiation of the whole breast. It is typically 
administered into the cavity created during lumpectomy, given intraoperatively during 
breast surgery, or interstitially via thin catheters threaded through breast tissue (Baglan et 
al., 2003; Williams, 2012). Patients receiving partial breast irradiation were excluded 






A radiation boost is an additional radiation treatment given to a portion of the 
whole breast treatment field. There are three main types of radiation boosts. They include 
the operative bed, mastectomy scar, and chest wall boost. Patients with close surgical 
margins are at greater risk of cancer recurrence in the operative (i.e., tumor) bed, so a 
larger boost is typically given over seven fractions; while more acceptable margins 
require a smaller boost given over five fractions (Williams, 2012). The intended purpose 






Ionizing radiation creates its effect by knocking or removing electrons from their 
orbits or shells around the atom, resulting in the atom becoming ionized. Photons are the 
primary type of ionizing radiation used for whole breast radiotherapy. Photons are a 
form  of electromagnetic radiation consisting of little packets of energy that are 
generated by a  linear accelerator (Ma, 2012). The photons travel through tissue and 
form ions in the atoms of the cells in the tissue. This change causes damage to the cell’s 
deoxyribonucleic  acid (DNA) by breaking the DNA chain leading to cell death or 
preventing cell replication (ACS, 2014). 
There are three stages in the cellular response to ionizing radiation exposure. The 
first stage is the physical response where ions are formed in the atoms of exposed tissue 
Ma, 2012). The second stage is the radiochemical response where highly reactive free 
radicals are formed (Ma, 2012). The third stage is the biologic response where DNA is 




no cell injury. Second, the cell may be repaired correctly. Third, a genetic mutation 
occurs and the cell may be repaired incorrectly. Fourth, the cell dies in response to 
radiation-induced damaged (Ma, 2012). 
Both benign and cancer cells respond differently to radiation exposure. Rapidly 
dividing cells such as those of the mucosa are particularly radiosensitive, while cells that 
divide more slowly such as those of the muscles are radioresistant (Ma, 2012). 
The trajectory of radiation changes on tissue has been described in the literature. 
For example, the International Commission on Radiological Protection (ICRP) drafted a 
report detailing radiation doses, target organs and tissues, radiation changes and the 
timing of their onset. See Table 2.1. Some tissues respond acutely and while other tissues 
respond much later to radiation therapy. An acute radiation response is seen within hours 
to days of exposure. The skin is a tissue that demonstrates an acute response to radiation 
therapy (Ma, 2012). Acute radiation breast skin changes occur within the epidermis 
(Jagsi, 2011). Breast “radiation results in deformation of the parenchyma; leading to 
retraction, fibrosis, vasculitis, and skin breakdown” (Churgin, Isakov, & Yetman, 2008, 
p. S24). 
A late response occurs months to years after radiation therapy. Breast tissue has a 
late response to radiation therapy (Ma, 2012). The skin may also exhibit a late response 
to radiation therapy related to damage of the dermis and vasculature (Jagsi, 2011); 
however, this study does not examine late onset radiation dermatitis. 
Acute radiation skin toxicity typically occurs in a predictable order. First, 
radiation therapy causes an inflammatory response, which leads to dilation of capillaries 




anemia mitigates radiation-induced skin erythema. Second, DNA damage to the germinal 
cells of the epidermis, hair follicles, and sebaceous glands leads to loss of the epidermal 
basal cells, epilation, and dryness of the skin (Lawenda & Johnstone, 2011). Third, 
erythema becomes more prominent as inflammatory cells migrate into the dermis 
(Lawenda & Johnstone, 2011). Fourth, the dry skin in the treatment field begins to peel 
causing dry desquamation. An increased amount of melanin is produced by melanocytes 
in the basal layer of the epidermis leading to hyperpigmentation (Lawenda & Johnstone, 
2011). Fifth, moist desquamation may occur if the cumulative radiation dose to the skin 
exceeds 40 Gray [Gy] (Lawenda & Johnstone, 2011). 
 
Patient Experience of Radiodermatitis 
 
Radiation dermatitis is a treatment-induced dose-limiting toxicity (Gosselin et al., 
2015). The National Cancer Institute (NCI, 2015) defines radiation dermatitis as “a skin 
condition that is a common side effect of radiation therapy. The affected skin becomes 
painful, red, itchy, and blistered" (NCI, 2015). Radiodermatitis can lead to treatment 
delay or early termination, lost work productivity, wound care costs, social isolation, and 
altered body image (Oncology Nursing Society [ONS], 2015; Schnur et al., 2012). Thus 
radiodermatitis can greatly impact quality of life (ONS, 2015). 
Knobf and Sun (2005) found women undergoing radiotherapy for breast cancer 
reported experiencing pain, twinges, skin changes, fatigue, sleep disturbances, and breast 
edema. Comparably, women in a study conducted by Wengström, Häggmark, Strander, 
and Forsberg (2000) described having pain, skin changes, and fatigue at the end of breast 
radiotherapy. Moreover, all of the participants in Knobf and Sun’s (2005) study 




cancer patients in a study by Berthelet et al. (2004) developed skin toxicity during 
external radiotherapy. 
 
Patient-specific Risk Factors for Breast Radiation Dermatitis 
 
The results of numerous studies conducted over the past two decades have 
identified predictors of radiation dermatitis development. Decades ago, Porock et al. 
(1998, 1999) found bra cup > D, body weight, smoking status, skin phototype, 
lymphocele aspiration, and history of cancer were associated with a severe skin reaction. 
More recently, De Langhe et al. (2014) found bra cup > D, body mass index (BMI) > 26, 
current smoking, genetic variation in MLH1, concomitant hormone therapy, 
normofractionation, and IMRT in the supine position modified the risk of developing 




Large breasts are consistently associated with increased risk of radiodermatitis. 
Studies that have considered breast size have primarily focused on cup size. However, 
most pairs of breasts are naturally asymmetrical, while bra cups are equal in size making 
the fit too large or small on one side. In addition, an investigation by Wood, Cameron, and 
Fitzgerald (2008) in Australia revealed 80% of the study population wore incorrectly 
fitting bras. Moreover, bra cup size may not identify the amount of breast ptosis (i.e., 
drooping). Pendulous breasts increase the surface area in the inframammary fold and 
cause a bolus effect during radiation therapy that predisposes the woman to radiation 
dermatitis (Algan, Fowble, McNeeley, & Fein, 1998; Barrett-Lennard &Thurstan, 2008). 




Few studies of radiation dermatitis have included breast measurements such as 
asymmetry and ptosis as variables. Liu, Luan, Mu, and Ji (2010) used medical imaging to 
calculate seven unique measurements of the breasts (i.e., nipple level, nipple to midline 
distance, inferior mammary fold level, breast width, breast projection, breast volume, and 
anterior chest wall projection) in 100 Chinese women. They found that 100% of the 
women had at least one of the seven parameters significantly different between the breast 
pairs. These issues support the need for a more precise measurement of the breast in 
research studies when breast size is used to predict an outcome such as radiation 
dermatitis. 
Although there are several scales used to measure radiation dermatitis, each 
instrument usually employs one global assessment of the breast treatment field to identify 
the maximum level of skin toxicity. However, Hidvegi, Nduka, Myers, and Dziewulski 
(2004) measured the torso surface area of 40 healthy women to estimate body surface area 
in burn victims and found that “for every increase in cup size, the surface area of a 
woman’s anterior trunk increased by a factor of 0.1 relative to her posterior trunk area”  
(p. 1595). These researchers found the pectoral region may account for 10% of the total 
body surface area when the bra cup size is greater than or equal to DD (Hidvegi, 2004). 
Therefore, there is a precedent for making multiple assessments of radiation skin toxicity 
(Hindley et al., 2014; Porock & Kristjanson, 1999; Roper, Kaisig, Auer, Mergen, Molls, 
2004). Using a single measurement of skin toxicity in the breast treatment field does not 
adequately quantify the body surface area impacted by radiodermatitis. The feasibility 





Body Mass Index 
 
Overweight and obesity are related to increased incidence of breast cancer (ACS, 
2015). They are also known risk factors for the development of radiation dermatitis 
(Pommier, Gomez, Sunyach, D'Hombres, Carrie, & Montbarbon,  2004; Twardella et al., 
2003). A BMI > 25 is overweight and BMI >30 is obese (Centers for Disease Control and 





A strong association exists between smoking during radiation therapy and the 
development of radiation dermatitis (Kraus-Tiefenbacher et al., 2012; NCI, 2015; Pignol, 
Vu, Mitera, Bosnic, Verkooijen, & Truong, 2015; Sharp, Johansson, Hatschek, & 
Bergenmar, 2013). Similarly, Fisher et al. (2000) found a history of lifelong tobacco 
abstinence was associated with a reduction (p = .026) of radiation dermatitis 
development. Smoking tobacco causes vasoconstriction of the cutaneous vasculature 
(Leow, & Maibach, 1998; Monfrecola, Riccio, Savarese, Posteraro, & Procaccini, 1998). 
This tobacco-induced vasoconstriction was scientifically measured using thermography, 
laser doppler flowmetry, plethysmography, videomicroscopy, pulse oximetry, and oxygen 




Fitzpatrick devised a system describing skin types according to risk of developing 
sunburn (Astner & Anderson, 2004). The system implements six phototypes that range 
from “do not tan, burn easily” to “become darker, do not burn” (Wolff & Johnson, 2009). 




phototype that often suffers the most severe radiation dermatitis (Pignol et al., 2008; 
Yamazaki, 2012). These findings suggest the need for additional studies to explore the 
use of skin phototype instead of race and ethnicity as a potential predictor of radiation 
dermatitis development. 
 
Assessment of Radiation Dermatitis 
 
Although there are several instruments used to measure radiation dermatitis, each 
instrument usually employs one global assessment of the breast treatment field by a 
radiation oncology health care provider. There is a precedent for making more than one 
assessment. Porock and Kristjanson (1999) assessed eight sites in the breast treatment 
field (i.e., sternum, axilla, upper outer quadrant, upper inner quadrant, lower outer 
quadrant, lower inner quadrant, nipple, inframammary fold). Hindley et al. (2014) 
measured radiodermatitis in three sites, including near the sternal notch, at three o’clock, 
and six o’clock on the breast. Röper, Kaisig, Auer, Mergen, and Motis (2004) assessed 
three sites in the breast treatment field (i.e., upper inner quadrant, upper outer quadrant, 
inframammary fold). They also measured skin surface dose in these areas, found a higher 
dose in the inframammary fold, and a lower dose in the other sites. This finding  
supported the importance of our plan to measure radiation dermatitis in more than one 
area of the breast. Also, capturing data on the specific location of radiation dermatitis 
allows for exploration the impact of radiodermatitis by severity and specific site in the 




Nonphysical Sequelae of Radiation Dermatitis 
 
The nonphysical sequelae of radiation dermatitis include treatment delays, early 
termination of treatment, suffering, and lost contributions to the family and society. Bese, 
Nut, Sut, and Ober (2007) found a significant difference (p = .022) in the 5 and 10 year 
locoregional control of breast cancer recurrence in favor of women with treatment 
interruptions of 0-7 as compared to > 8 days. Advanced cancer leads to patient suffering 
(Cherny, 2009). Illness and premature death of breast cancer patients leads to loss of 
wages by the patient and family members, loss of contributions to society, caregiving 
burden on family members, and loss of the patient’s role within the family (Yabroff, 
Lund, Kepka, & Mariotto, 2011). 
There are often unrecoverable costs to the patient related to radiation dermatitis 
(McQuestion, 2006). Schnur, Ouellette, Bovberg, and Montgomery (2012) estimated the 
mean out of pocket cost of skin toxicity during external beam radiation therapy for breast 
cancer was $131.64 per patient. Sixty-six percent of the women in the study by Schnur et 
al. (2012) reported the need to purchase topical products, special soaps, and bandages to 
manage radiation dermatitis. Additionally, 58% spent money on new bras that provided 
comfort during therapy, replacement of bras ruined by topical creams or skin markers, or 
new cotton clothing such as a tee shirt. The costs of purchasing the products and clothing 
are not covered by health insurance plans and are not eligible expenses for flexible 
spending accounts (FSAs). In order to utilize money efficiently and reduce human 
suffering, it is crucial to determine the efficacy of topical agents that may help prevent or 
manage radiation dermatitis. The measures tested in this study will be utilized in future 




Global Quality of Life 
 
Most studies on cancer-related quality of life have focused on cancer survivors 
who have completed treatment, not those actively receiving treatment. However, it is 
important to study QOL among patients actively receiving treatment because QOL data 
can be used to predict the onset of cancer treatment-related toxicities (Halyard, Frost, 
Dueck, & Sloan, 2006). Additionally, QOL data can be used as an endpoint in cancer 
clinical trials and to guide clinical care as laboratory data do (Halyard et al., 2006). 
QOL may decrease or increase in the presence of high toxicity level (Huschka & 
Burger, 2006). This may occur when bulky cancer is present. Cancer treatment may cause 
toxicity such as neutropenia while at the same time reducing tumor size and decreasing 
pressure on nearby structures. This scenario suggests the need for measurement of  
toxicity and QOL during cancer clinical trials. 
 
Skin-related Quality of Life 
 
Few studies have examined the impact of breast radiodermatitis on QOL as a 
primary outcome. In a pilot study by Schnur, Ouellette, Bovberg, and Montgomery 
(2009), breast cancer patients receiving radiotherapy perceived there is a time when 
symptoms should appear and a time when those symptoms should resolve. These patients 
feared the symptoms might never end, that they were possibly receiving the wrong 
treatment, or the cancer may recur. Also, the patients perceived themselves as physically 
repulsive and felt guilty about not being able to do everything they did before the breast 
cancer diagnosis. In a second larger study, breast cancer patients commented that 
sunburns go away, but radiation burns keep getting worse. They were anxious for their 




Montgomery, 2011). Lighter skinned women talked about their skin getting red, for 
example, “you couldn’t even find the nipple on my breast” (Schnur et al., 2011, p. 263). 
Darker skinned women commented about their skin getting darker, for example, “dark 
and ugly, too dark, like toast when it burns, black and crispy, burnt, and charcoal” 
(Schnur et al., 2011, p. 263). The women voiced concerns about discomfort, treatment 
interruptions because of radiation dermatitis, and lengthened treatment plans caused by 
the treatment interruptions (Schnur et al., 2011). They often needed to adapt their 
clothing and this impacted their social activities. The women commented about having to 
go braless, changing from an underwire bra to one without an underwire, wearing a 
camisole or undershirt; or needing to wear loose clothing, only black bras, or old t-shirts 
because of greasy, oily skin creams (Schnur et al., 2011). Large breasted women 
discussed inability to go to church and family functions such as weddings because they 
were unable to wear an underwire bra (Schnur et al., 2011). This finding was also 
supported by the study of a topical agent to prevent radiation dermatitis in breast cancer 
patients. Of the 42 patients who completed the study, 44% reported having trouble 
wearing a brassiere by the end of radiation treatment (Szumacher et al., 2001). These 
results of these studies demonstrate the detrimental impact of radiodermatitis on skin- 
related QOL. Further, skin-related QOL needs to be measured as a primary outcome in 
studies of radiodermatitis. 
 
Significance of Study 
 
Radiation dermatitis is a significant concern for women receiving radiotherapy for 
breast cancer and their health care providers. The only evidence-based guideline for  




prevent infection (Roy, Fortin, & Larochelle, 2001). There are no clear guidelines for the 
prevention and management of radiation dermatitis of the breast. Expanding the 
assessment of breast skin toxicity to include seven areas within the treatment field may 
increase our ability to detect small but clinically significant changes during future clinical 
trials of agents that may prevent or manage radiation dermatitis. In addition, the patient’s 
perspective is an important component of the radiation dermatitis experience. Measuring 
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doses (Gy) Time of Onset 
 
 
Early transient erythema 2 2-24 hours 
 
Main erythema reaction 6 ~1.5 weeks 
 
Temporary epilation 3 ~3 weeks 
 
Permanent epilation 7 ~3 weeks 
 
Dry desquamation 14 ~4-6 weeks 
 
Moist desquamation 18 ~4 weeks 
 
Secondary ulceration 24 >6 weeks 
 
Late erythema 15 8-10 weeks 
 
Ischaemic dermal necrosis 18 >10 weeks 
 
Dermal atrophy (1st Phase) 10 >52 weeks 
 




>152 >52 weeks 
 
International Commission on Radiological Protection. (2011). Draft: Early and late 
effects of radiation in normal tissues and organs: Threshold doses for tissue reactions  and 















We conducted a longitudinal, mixed methods, pilot and feasibility study. Measures 
to be used in a larger study were piloted and we examined the feasibility of our measures. 
Measurements of skin toxicity and skin-related quality of life (QOL) were  taken at 
baseline and repeated during weekly radiation therapy. Global QOL was  measured at 
baseline and repeated at the 5th week of radiotherapy. Change was measured within each 
participant. The validation process for use of the Dermatology Life  Quality Index   
(DLQI) in breast radiodermatitis was initiated. A content analysis was  conducted on 




We hypothesized that whole breast external radiotherapy, physical characteristics 
such as skin phototype and breast size, and lifestyle behaviors including smoking and 
body mass index (BMI) would influence the physical changes that are collectively 
described as radiodermatitis. We further hypothesized that radiodermatitis would impact 
skin-related and global QOL. A conceptual model that illustrates our study design is 




knowledge and the components are supported by studies reported in the professional 
literature. For example, conventional external beam radiotherapy of the whole breast 
(Pignol et al., 2008), physical characteristics including skin phototype (Yamazaki et al., 
2011) and breast size (Algan, Fowble, McNeeley, & Fein, 1998; Barrett-Lennard, 
Thurstan, 2008; De Langhe et al., 2014; Pommier, Gomez, Sunyach, D’Hombres, Carrie, 
& Montbarbon, 2004), and lifestyle- related factors such as obesity (De Langhe et al., 
2014) and being a current smoker (De Langhe et al., 2014; Sharp, Johansson, Hatschek, & 
Bergenmar, 2013; Wells et al., 2004) are postulated risk factors for radiodermatitis 
development. Radiodermatitis impacts skin-related QOL. It often results in physical 
discomfort (Gosselin et al., 2015; Knobf &, Sun, 2005; Schnur, Ouellette, Bovberg, & 
Montgomery, 2009; Schnur, Ouellette, Dilorenzo, Green, & Montgomery, 2011; 
Wengström, Häggmark, Strander, and Forsberg, 2000), bother from radiodermatitis 
treatment (Schnur et al., 2011), and impacts clothing selection  (Schnur et al., 2011, 
Schnur et al., 2012). Global QOL may also be impacted by radiodermatitis. Domains of 
global QOL negatively affected by radiodermatitis include physical well-being (Schnur et 
al., 2011; Sutra, Tan, Freedman, Troxel, & Lin, 2013; Welzel et al., 2013), psychological 
well-being (Schnur et al., 2011), social well-being (Schnur et al., 2011), and spiritual 
well-being (Schnur et al., 2011). Additionally, radiodermatitis and poor QOL can lead to 
delays or early termination of radiotherapy, which impacts treatment efficacy (Bese, Nut, 








This study was conducted at a single site in the department of radiation oncology 
at an American College of Surgeons Commission on Cancer accredited Comprehensive 
Community Cancer Program located in northern Illinois. The cancer program had 216 





Ethical approval was gained from the University of Utah Institution Review 
Board (UIRB), Salt Lake City, Utah, USA. A reliance agreement was created between 
the UIRB and the health care system affiliated with the cancer program. All participants 
gave informed consent before inclusion in the study. The data were stored digitally on a 
secure, password-protected, encrypted, external hard drive. The paper consent forms and 




It is appropriate to recruit a purposive sample for a pilot descriptive study of 
women with breast radiodermatitis (Trochim & Donnelly, 2008). Therefore, a purposive 
sample of 41 English-speaking adult women with stage 0-III breast cancer identified as 
candidates for external beam radiotherapy were accrued to the study from May 2014 
through May 2015. One participant withdrew from the study during the 1st week. All of 
the remaining 40 participants were followed from baseline to completion of radiotherapy 




Inclusion and Exclusion Criteria 
 
A full listing of the study inclusion and exclusion criteria is provided in the study 
schema illustrated in Figure 3.2. Study participation was restricted to female participants 
18 years or older since breast cancer is rare in men and children. Less than 1% of breast 
cancers occur in men (Giordano, Cohen, Buzdar, Perkins, & Hortobagyi, 2004)  and men 
with breast cancer rarely require radiotherapy to manage their disease (Borgen et al., 
1992). Similarly, less than 0.1% of all breast cancer cases occur in children or  
adolescents (Gutierrez, Housri, Koniaris, Fischer, & Sola, 2008). 
Cases of inflammatory breast cancer and Paget’s disease of the nipple were 
excluded from the study because those conditions may appear very similar to radiation 
changes in breast skin. Additionally, participants with an inflammatory skin condition 
present on the breast were excluded from the study. 
Stage IV breast cancer typically represents metastasis to the brain, bones, or lungs 
and is treated with radiation therapy to the metastatic site(s). For that reason, cases of 
stage IV breast were excluded from this study. Any stage of breast cancer requiring 
external radiation therapy to the breast was eligible for this study. Moreover, the 
participant must have been scheduled to receive, but had not yet started, external beam 
breast radiation therapy; those receiving partial or no breast irradiation were excluded. 
The principal investigator speaks only English and the radiation skin changes form 
was  available exclusively in English. Consequently, study participation was restricted to 




Sample Size and Sensitivity Analysis 
 
Recommended sample size for pilot studies is a contentious topic and suggestions 
have ranged from 12 subjects per arm to totals of 30 to 50 subjects (Julious, 2005; 
Lancaster, 2004; Sim & Lewis. 2004). We sought to have sufficient power to accurately 
detect significant differences in our larger pilot study looking at the impact of 
radiodermatitis on skin-related quality of life. However, we did not have a good estimate 
of this effect. A sensitivity analysis was conducted using G*Power version 3.1.9.1, with a 
sample size of 40 participants in one group, .10 alpha level of significance, power of .80, 
epsilon of 1.0, correlation of .50, and six repeated measurements. Using these parameters, 
we could expect to detect an effect size of .15, which is a small effect size using Cohen’s 
criteria (Cohen, 1992). Since we planned to conduct a descriptive feasibility and pilot 
study, a slightly relaxed level of significance was acceptable in that it help us avoid 
missing small but clinically significant differences. Similarly, Rubenstein et al. (2005) 
argued that a relaxed level of significance is appropriate to a phase II study in that it 




The external treatments were delivered via a Varian Clinac EX linear accelerator 
using 3-dimensional conformal techniques, including stand open field, hard and enhanced 
dynamic wedges, and irregular surface compensation. All of the patients were treated in 
the supine position using photons. Thirty-three women received normofractionated (i.e., 
180-200 cGy) doses and 7 women received accelerated treatment using fractions of  266 




at the start of the study. The cumulative radiation dose, energy, fraction number, use of a 
breast immobilizer or bolus pad was recorded weekly. 
 
Instruments, Forms, and Measures 
 
This section focuses on the study instruments, forms, and measures. A tabular 
overview of the study tools to be used in the proposed study can be found in Table 3.1. 
All of the data were collected using hard copies of the instruments and forms. 
A packet of baseline surveys and forms in addition to the weekly Dermatology 
Life Quality Index (DLQI) forms were given to the participant after consent was 
obtained. The participant was allowed to complete the forms at home or at the cancer 
center and return the baseline forms to the PI on the first day of radiotherapy. Further, the 
participant was asked to return a completed DLQI “form” each week on the day of skin 
assessment. 
 
Measurement of Radiation Dermatitis 
Radiation Therapy Oncology Group (RTOG) Acute Morbidity 
Scoring Criteria--Skin 
 
The acute version of the morbidity scoring criteria for radiation skin reactions was 
developed in 1985 by the RTOG to complement the existing version for scoring chronic 
skin reactions and is a standard of care in the radiation oncology community (Cox, Stetz, 
& Pajak, 1995; Pires, Segreto, & Segreto, 2008). These scoring criteria include five 
ranked responses from zero—no change over baseline to four—ulceration, 
hemorrhage,  and necrosis. The Radiation Therapy Oncology Group (RTOG, 2015) 




toxicity in our  study. See Figure 3.3. The PI was the sole rater of skin toxicity. Skin 
toxicity was measured at baseline to establish the normal appearance of skin in the 
radiation treatment  field before radiotherapy commencement, typically at the 
simulation visit. 
 
Maximum Skin Toxicity 
 
The maximum grade of skin toxicity in the radiation treatment field was assessed 
at baseline and weekly during radiotherapy by the PI using the RTOG Acute Radiation 
Morbidity Scoring Criteria for skin (RTOG, 2015). This single measurement of 
maximum skin toxicity (i.e., RTOG score) is used in clinical settings and research 
studies. 
 
Breast Skin Assessment Form (BSAF) 
 
Using a single measurement of the maximum radiodermatitis grade has 
limitations. It does not take into account the amount of body surface area and the location 
of radiodermatitis. The BSAF is an investigator-developed data collection form. It allows 
documentation of the RTOG skin toxicity score among seven areas in the breast radiation 
field (i.e., upper and lower outer quadrant, upper and lower inner quadrant, inframammary 
fold, sublavicular area, and axilla). These seven areas were assessed at baseline             




Fitzpatrick devised a system describing skin types according to risk of developing 
sunburn (Astner & Anderson, 2004). The potential ratings included the following: type I—




burns moderately, tans uniformly, type IV—burns minimally, always tans well, type V— 
rarely burns, tans profusely, and type VI—never burns (Wolff & Johnson, 2009). For this 





Height and weight were measured at baseline; then the BMI was calculated using 
the online Centers for Disease Control and Prevention (2015) Adult BMI Calculator. 
Participant-reported bra cup and band size was recorded. The PI measured the length of 
the affected breast in women who underwent lumpectomy or mastectomy with immediate 
reconstruction. The contralateral breast was measured in women who underwent 
mastectomy without reconstruction. The measurement was standardized by using the 
midclavicular line as a landmark, then measuring the breast length from inframammary 
fold to nipple in centimeters using a 72” disposable paper measuring tape. The PI 
measured the breast length for each participant. A case of 500 Medline measuring tapes 
was ordered to ensure the use of a standardized measurement tool throughout the study 
while reducing the risk of communicable diseases. 
 
Measurement of Quality of Life 
Dermatology Life Quality Index (DLQI) 
The purpose of the DLQI is to provide a simple and reliable instrument that can 
be easily and routinely administered in a clinic setting for any skin condition. It was 
translated into 55 languages and used for at least 33 skin conditions (Basra, Fenech, Gatt, 




120 dermatology patients who answered an open-ended question about how their skin 
condition impacted their life (Finlay & Khan, 1994). Next, 49 aspects of impact on life 
were identified in the first 70 responses (Finlay & Khan, 1994). No new aspects emerged 
in the remaining 50 responses (Finlay & Khan, 1994). The aspects were ranked by 
frequency of citation and 10 aspect-based questions were developed (Finlay & Khan, 
1994). The 10-item instrument was piloted in 20 patients, revised slightly, and then 
piloted again in another 20 patients (Finlay & Khan, 1994). The DLQI contains 10 scaled 
items including one that is partly dichotomous. The scaled items focus on physical 
sensations; embarrassment; interference with activities at home; clothing selection;   
impact on social activities; difficulty participating in a sport; causing a problem at work  
or school; causing a problem with relationships among close friends, relatives, or a 
partner; sexual difficulties; and impact of treatment on life and lifestyle. The dichotomous 
item inquires whether or not the skin condition prevented the respondent from attending 
work or school. The 10 DLQI items can be grouped into six subscales for analysis 
including: 1) symptoms, feelings [items 1 & 2], 2) daily activities [items 3 & 4], leisure 
[items 5 & 6], work/school [item 7], personal relationships [items 8 & 9], and treatment 
[item 10] (Finlay & Khan, 1994). Eight of the scaled items include options of “very 
much,” “a lot,” “a little,” “not at all,” and “not relevant.” Two additional items include 
the previous options except “not relevant.” A DLQI cumulative score of 0-1  represents 
no effect, 2-5 represents a small effect, 6-10 represents a moderate effect, 11-  20 
represents a very large effect, and 21-30 represents an extremely large effect on the 
patient's life (Department of Dermatology, 2011). 




items in a scale measure the same construct and is expressed in the form of Cronbach’s 
alpha with scores ranging from .0 to 1.0. A high Cronbach’s alpha suggests the instrument 
is consistent and reliable. A score of at least .70 is desirable (DeVellis, 2003)  and .80 is 
preferable (Pallant, 2010). Conversely, a score of 1.0 suggests the presence of  redundant 
items. A study of the DLQI in patients with eczema, an inflammatory skin  condition 
similar to radiation dermatitis, revealed a Cronbach’s alpha of 0.83 (Badia,  Mascaro, & 
Lozano, 1999), a good-to-excellent score. A review of 22 studies using the DLQI for 
psoriasis, acne, burn scars, urticaria, melasma, and other dermatologic  conditions yielded 
a Cronbach’s alpha range of 0.75 to 0.92 (Basra et al., 2008). 
Validity is the extent to which an instrument measures what it is intended to 
measure. The degree to which an instrument adequately samples the phenomenon of 
interest is known as content validity. The DLQI was originally developed from the input 
of 120 dermatology patient’s responses to the request, “Please could you write down all 
the ways that your skin disease affects you” (Finlay & Khan, 1994, p. 210). This process 
ensured the content of the DLQI contained items that dermatology patients deemed 
important to their QOL. Next, the DLQI was pilot tested in 20 patients and minor 
changes were made (Finlay & Khan, 1994). Finally, the DLQI was tested in another 20 
patients to verify content validity (Finlay & Khan, 1994). 
Face validity focuses on whether an instrument measures what it proposes to 
measure (Doordan, 1998). Face validity is a subjective measure, while content validity is 
an objective measure of the instrument’s adequacy in measuring the phenomenon of 
interest. 




solicited feedback on the DLQI from expert 12 radiation oncology nurses at a local 
chapter meeting of the Oncology Nursing Society. A hard copy of the DLQI was given to 
each nurse. Each nurse was instructed to read the items on the DLQI and provide written 
feedback on the items. 
 
Quality of Life Instrument—Breast Cancer Patient Version 
 
This instrument measures global QOL in patients with breast cancer. The scale 
consists of 46 items with ordinal ranked responses. The 46 items measure four domains  
of QOL including physical, psychological, and spiritual well-being, plus social concerns. 
The QOL Instrument—Breast Cancer Patient Version is based on the QOL Instrument— 
Cancer Survivor (QOL-CS). One question focusing on concern about female relatives’ 
risk of developing breast cancer was added to the original version. The original QOL-CS 
was developed from items on a survey mailed to 686 cancer survivors, including 294 
survivors of breast cancer (Ferrell & Grant, 2003). Test-retest reliability was measured by 
selecting a random sample of 150 from the original 686 participants. The test-retest 
reliability for the entire QOL-CS tool was r = 0.89 and for the subscales was r =0.88 for 
physical well-being, r =0.88 for psychological well-being, r =0.90 for spiritual well- 
being, and r =0.81 for social concerns. Internal consistency was measured using 
Cronbach's alpha coefficient to quantify the level of agreement between the items and 
subscales. Ferrell, Hassey Dow, and Grant, (1995) found r =0.93 for the entire scale and 
alphas of r =0.71 for the spiritual, r =0.77 for the physical, and r =0.89 for the 
psychological well-being; r =0.81 for the social concerns subscales (Ferrell et al., 1995). 
A panel of QOL researchers and oncology nurses assessed the content validity of the 




the variance in global QOL (Ferrell et al., 1995). Pearson correlations were used to 
measure parallel validity between the QOL-CS scale and subscales and the already 
established Functional Assessment of Cancer Therapy-General (FACT-G) scale and 
subscales. The correlation between the two overall scales was r = .78, the physical 
subscales was r = .74, the social subscales was r = .44, and QOL-CS psychological to 
FACT-G emotional was r = .65 (Ferrell et al., 1995). The FACT-G does not have a 
spirituality subscale. Global QOL was measured in our study using the Quality of Life 
Instrument—Breast Cancer Patient Version at baseline and at 5 weeks on treatment  when 
the peak severity of radiation dermatitis was expected to begin. 
 
Radiation Skin Changes Questions Form 
 
These questions were designed for this study to delineate differences in constructs 
on the first item of the DLQI (i.e., itching, pain, stinging) in relation to radiation 
dermatitis and to explore convergence or divergence between the participant’s responses 
on the DLQI items and her narrative response to how each item on the DLQI impacted 
her life. The participant was asked to describe the impact of the given DLQI item on her 
life in writing on the form. The participants completed this form during the 5th week of 
radiotherapy. 
 
Measures Implemented to Minimize Missing Data 
 
Missing data compromises the validity of study data and findings. External beam 
radiation therapy is typically delivered daily Monday through Friday. The principal 
investigator endeavored to collect the weekly measurements on Mondays. This strategy 




Friday) to collect data missed on Monday. 
 
 
Measures Implemented to Maximize Data Security 
 
Each participant was assigned a unique identifier. The unique identifier was used 
on all study forms and in the database instead of personal identifiers. Hard copies of 
primary data sources were stored in locked water-proof and fire-proof safe in the 
principle investigator’s (PI) locked office. There was only one clinical site for this study. 
The log that linked the participant to the data was saved to the cancer program’s tumor 
registrar’s password protected secured server. The primary data sources (i.e., study 
forms) with unique identifiers were transported via a locked suitcase from the radiation 
oncology department to the PI’s automobile and locked in the trunk before transport to 
the study computer. De-identified data from the study forms were manually entered into 
the database by the PI on a password-protected, encrypted computer and stored on a 
secured server. The principal investigator (PI) was the only individual with access to the 
password and encrypted database. 
 




The IBM Corporation (2012) Statistical Package for the Social Sciences (SPSS) 
Statistics for Windows Version 21.0 was used to create a database and analyze the 
quantitative data collected. 
 
Clinical Significance Determination 
 
The determination of a statistically significant difference or change is made using 




Wiersma, & Jurs, 2003). However, the determination of a clinically significant difference 
or change is dependent upon the unique patient, the patient’s disease status, the patient’s 
perception about QOL within the context of her or his situation, and the viewpoint of the 
healthcare provider (Symonds, Berzon, Marquis, & Rummans, 2002). Osoba (2011) 
commented that currently there is no “clear method for determining the clinical 
meaningfulness of changes in scores” (p. 57). However Frost, Bonomi, Ferrans, Wong, 
and Hays (2002) remarked that a clinically significant change is one perceived as 
beneficial or detrimental, important, or a reason to seek healthcare or a change in 
healthcare. In addition to the need to identify a clinically significant change in one score, 
there is the challenge of determining the meaning of change over multiple points in time 
(Cella, Bullinger, Scott, & Barofsky, 2002) and identifying change in qualitative 
information without interjecting researcher bias. Triangulation is used to establish 
convergent validity between qualitative and quantitative data (Hussein, 2009). 
Triangulation “simply means that a particular phenomenon is assessed in multiple 
modalities” (Knauper & Klein, p. 125). We used participant ratings on the DLQI and 
their narrative feedback on the radiation skin changes form to triangulate our results and 
estimate the convergent validity of the DLQI. 
 
Analysis of Research Questions 
 
Specific Aim 1 
 







To determine the feasibility of recruiting, enrolling, and following women with 
breast cancer who are being treated with whole breast radiotherapy across six time points: 
The framework created by Thabane et al. (2011) informed the assessment of the  




Pilot a collection of measures planned for use in a larger future study: A number 
of measures typically used in studies of breast radiodermatitis were piloted. We also 
conducted a pilot test of two new measures, clinician-measured breast length and ratings 
of skin toxicity using the RTOG grade in seven areas of the treatment field. Additionally, 
we explored participant tolerance of completing the DLQI weekly and the COH-QOL- 




Explore the utility (i.e., usefulness) of clinician-measured breast length (i.e., 
distance between the inframammary fold and nipple) and participant-reported bra cup 
size in the development of radiodermatitis over time on treatment and the efficacy of 
using multiple measurements of skin toxicity in the treatment field. Each participant’s 
breast length was measured by the PI. The resulting value was used as a variable in the 
correlation and as a comparator to participant-reported bra size in a table. A one-way 
within-subjects repeated measures ANOVA was conducted to compare skin toxicity 
grade of the breast using the RTOG scoring system by each individual area in the 









Calculate effect sizes to allow a scientific estimate of the sample size needed for 
the future study: The effect size for RTOG score by site in the radiation field was 
calculated during the one-way within-subjects repeated measures ANOVA. Kendall’s tau 
is a nonparametric correlation used instead of a Spearman Rho correlation when the 
sample size is small and there are tied ranked scores (Field, 2009a). Therefore, a  
Kendall’s tau correlation was performed to measure the relationship between factors and 
the severity of radiation dermatitis at 5 weeks on external radiotherapy of the breast  since 
our sample was small. However, effect sizes can be calculated by squaring the value of r 
from the Kendall’s tau correlation (Walker, 2003) 
 
Specific Aim 2 
 
Investigate the impact of breast radiodermatitis on skin-related and global quality 




Explore the relationship between skin-related and global quality of life among 
women experiencing breast radiodermatitis: A Kendall’s tau correlation was conducted to 







Describe the change in skin-specific and global quality of life (QOL) among 
women undergoing external radiation therapy for breast cancer between baseline and at 
week 5 on radiotherapy: Paired t-tests were used to measure the change in skin-related 
and global QOL from baseline to the 5th week on radiotherapy. 
 
Specific Aim 3 
 
Initiate the validation process of the Dermatology Life Quality Index (DLQI) 




Measure the participant agreement between the responses to the DLQI items and 
narrative feedback regarding the impact of constructs represented by the DLQI among 
women with breast radiodermatitis at the 5th week of radiotherapy: We measured the 
concurrent validity of the DLQI by assessing the agreement between participant’s 
responses on the DLQI and their narrative responses to a survey about the DLQI, both at 
5 weeks on radiotherapy. Participant agreement was measured at 5 weeks on  treatment 
when skin toxicity begins to peak. An extra copy of the DLQI and the only copy of the 
radiation skin changes form were given to the participant. Each woman was instructed to 
look at the extra copy of DLQI. Next, participants were invited to write  narratives about 
how each item on the DLQI impact their life. Thirty-one (78%) of the 40 participants 
provided narratives. The principal investigator (PI) abstracted the week 5 responses and 
the narratives on impact and entered the data into a form with a column for  the ordinal 




copy of the narrative, and a column for researcher rated level of agreement. Three 
researchers jointly coded the agreement score for each DLQI participant rating and 
narrative for the first participant. Subsequently, each researcher coded her perceived level 
of agreement for the remaining participant responses independently. The PI combined the 
agreement ratings by each researcher into one master document. The document was 
shared with each researcher, the agreement ratings were discussed, and consensus formed 




Appraise the content validity of the DLQI when used in radiation oncology. In 
this study, it was assessed by soliciting feedback on the DLQI from expert 12 radiation 
oncology nurses at a chapter meeting of the Oncology Nursing Society. A hard copy of 
the DLQI was given to each nurse. The nurse was instructed to read the items on the 
DLQI and provide written feedback on the items. The radiation oncology nurses did not 
recommend the addition or deletion of any DLQI items. They suggested a few minor 
word changes. For example, “not relevant” might be changed to “does not apply.” We 
determined the content validity of the DLQI was sufficient for use in our study based on 




Assess the construct validity of the DLQI using principal component analysis: 
Construct validity focuses on the extent that items on a measure such as the DLQI are 
consistent with the concept of interest (Soeken, 2010). It was assessed using principal 




ratios are suggested in the professional literature, ranging from 3 to 15 participants for 
each factor (Catell, 1978; Gorsuch, 1983; Pearson & Mundform, 2010; Pett, Lackey, & 
Sullivan, 2003; Nunally, 1978). We had 40 participants and five subscales yielding a 
ratio of 8:1. Our sample size adequacy was also estimated post hoc by examining the 
Kaiser-Meyer-Olkin (KMO) statistic and communalities after extraction, both with values 
greater than 0.5 if the sample size is adequate (Field, 2009). The SPSS computer 
application removed the work and study subscale from the PCA because the variance in 




Estimate the reliability of the DLQI when used in our population of women with 
breast radiodermatitis: The reliability of the DLQI subscales was assessed using a 
Cronbach’s alpha analysis and examining the interitem correlations. An alpha of 0.7 or 
higher and interitem correlation of 0.3 or greater was considered acceptable (Fields, 
2009b). 
 
Specific Aim 4 
 
Describe the thoughts and experiences of women experiencing radiation 
dermatitis of the breast at a cancer program in a community setting as associated with 
skin-related quality of life: Using directed content analysis, we measured the content 
validity of the DLQI for use in women with breast radiation dermatitis. 
Participants in the main study were asked to complete an open-ended survey 
about items on the Dermatology Life Quality Index instrument (Department of 




“Which issue is most important and why?” The survey was provided in hard copy at the 
5th week on radiation therapy when radiodermatitis was likely to start peaking. The 
participant was asked to complete the survey and return it within one week. The 
handwritten responses were transcribed verbatim into a single digital text file by the first 
author. 
Our goal was to gain a greater understanding of patient-reported skin-related 
quality of life in the presence of breast radiodermatitis. A qualitative content analysis 
approach was implemented. This research method uses a flexible yet systematic 
classification process of coding and identifying themes to permit the subjective 
interpretation of the content of data (Hsieh, & Shannon, 2005). However, reliability is 
also important (Schreier, 2012). 
Each member of the investigative team independently reviewed all of the 
comments. A list of initial codes was generated during telephone conferences and via 
email conversations. The first and second author independently assigned codes to the  
data. The responses were divided to represent one unique concept. None of these concepts 
were assigned more than one code. The third author reviewed the coded data and  
provided input. The results were discussed and consensus was reached. The first author 
reviewed the coded data to identify final codes and overarching themes. Since the 
participant was completing a survey about the 10 items on the DLQI, the six conceptual 
domains of this instrument (i.e., symptoms and feelings, daily activities, leisure, work and 
school, personal relationships, and treatment) influenced participant’s responses and 
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The BSAF is a data collection form. It features a diagram of the breast and seven specific sites in 
the typical breast radiation field (i.e., upper medial quadrant, upper lateral quadrant, lower medial 
quadrant, lower lateral quadrant, inframammary fold, axilla, and subclavicular area) that are 
evaluated using the RTOG Acute Morbidity Scoring Criteria—Skin. It also has an area to record 







The cumulative radiation dose was be recorded on the Breast Skin Assessment Form at each 
measurement period. This information will be obtained from the treating Radiation Therapist or 





Quality Index (DLQI) 





The skin phototype was calculated by recording the participant’s eye and natural hair color, and 
history of freckling, sun-burning, or sun-tanning. 
Researcher Single, measured 
at baseline 
Breast Length Using the midclavicular line as a landmark, the breast length from inframammary fold to nipple in 
centimeters using a 72” disposable paper measuring tape. 
Researcher Single, measured 
at baseline 
Quality of Life 
Instrument--Breast 







This is a 46-item scale that measures QOL among breast cancer patients. The 46-items are divided 
among four domains (i.e., psychological, physical, and spiritual well-being, and social concerns. 
 
These questions are designed to delineate differences in constructs on the first item of the DLQI 
and to explore convergence or divergence between the participant’s responses on the DLQI and 
their narrative responses to the questions. 
This single-item, 5-point scale was developed by the Radiation Therapy Oncology Group to 
objectively assess skin toxicity during therapeutic radiation treatment. 
Participant Repeated; 
baseline, week 5, 
 
Participant Single, measured 















Rationale for Conducting a Pilot and Feasibility Study 
 
 
Main Reason Explanation 
 
Process To assess the feasibility of the processes key to the success of larger, funded future studies 
--Recruitment of women with breast cancer receiving radiotherapy 
--Retention rates of women with breast cancer receiving radiotherapy 
--Refusal rates 
--Appraisal of eligibility criteria 
--Determine the best process for larger studies 
 
Resources Assess time and resource problems that might occur in larger, funded future studies 
--Determine the actual length of time required to complete study measures 
--Participant 
--Research team 
--Determine the human resources required for larger studies 
--Type of research team members needed 
--Number of each type of research team members needed 
 
Management Identify human and data management problems before commencing a larger study 
--Appraisal of study measures 
--Additions needed? 
--Deletions needed? 
--Identify problematic items before commencing a larger study 
--Are there any problems entering data into database? 
 
Scientific Identify the effect of external breast radiotherapy on women 
--Calculate change in skin toxicity score from baseline to 5 weeks after baseline 
Identify the effect of radiation dermatitis on QOL in women 
--Calculate change in QOL score from baseline to 5 weeks after baseline 
Use this information to conduct power analysis to estimate sample size requirements for 






































Measures   








Radiation Skin Changes Form 
 
Completed at: 





baseline & week 5 
 








Stage IV breast cancer
Inflammatory breast cancer
Paget disease 
Receiving partial breast irradiation 
< 18 years old 
Inflammatory skin condition currently
present on the breast 
Inclusion Criteria 
Stage 0 to III breast cancer 
Invasive ductal or lobular, DCIS histology
Receiving adjuvant EBT 
Status post mastectomy or segmentectomy 




























FEASIBILITY AND PILOT STUDY EVALUATING IMPACT OF CLINICIAN- 
MEASURED BREAST LENGTH ON RADIODERMATITIS AND VALUE 
OF MULTIPLE LONGITUDINAL SKIN ASSESSMENTS 
IN THE TREATMENT FIELD 
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We explored the role of clinician-measured breast length and bra cup size in the 
development of radiodermatitis over time on treatment and the efficacy of using multiple 
measurements of skin toxicity during radiotherapy as an outcome in a pilot study. The 
feasibility of measures to be used in a larger future study was assessed then described 
quantitatively and narratively. 
 
Methods and Materials 
 
We studied women receiving normofractionated or accelerated external 
radiotherapy provided in the supine position using 3-dimensional conformal techniques at 
a community cancer center in northwestern Illinois in this descriptive study. Acute skin 
toxicity was assessed using the RTOG scale in 7 areas within the treatment field across 6 
time-points. The total score for the 7 areas was calculated each week. Breast length was 
measured, used as a variable to describe its role in the development of acute 
radiodermatitis in the 7 areas within the treatment field, and compared against reported bra 
cup size. Repeated-measure ANOVAs examined radiodermatitis using maximum skin 
toxicity and 7 sites in the radiation treatment field over 6 time-points. Kendall’s tau 




Forty women (39 non-Hispanic White, 1 Asian) consented to this study. Increase 
in breast length significantly correlated with increase in maximum RTOG score (p = .04); 




quadrant (p = .02), lower lateral quadrant (p = .02), inframammary fold (p = .001); with 
increasing BMI (p = .002) and bra cup size (p = .0003). The clinician-measured breast 
lengths and participant-reported bra cup sizes were discordant. Overall, our study 




Our results suggest that measuring breast length and multiple areas in the 
treatment field is feasible and may increase the sensitivity of skin toxicity assessment. 
Additional larger studies among diverse populations are needed to determine both the 
clinical significance of the sum of RTOG scores for 7 areas in the radiation treatment 
field and the utility of multiple individual scores in the treatment field and clinician- 




Previous studies of radiodermatitis are limited in that they are typically conducted 
at major medical centers in urban areas. Additional studies are needed in community 
settings. 
Predictors of radiation dermatitis development have been identified over the past 
two decades of research. The predictors that were consistently associated with 
radiodermatitis development include breast characteristics, body mass index, smoking, 
and skin phototype. 
The purpose of this study was to explore the role of clinician-measured breast 
length and participant-reported bra cup size in the development of radiodermatitis over 




treatment as an outcome in a pilot study. Additionally the feasibility of measures to be 




Large breasts are consistently associated with increased risk of radiodermatitis.1-3 
However, few studies of radiation dermatitis have included breast measurements such as 
asymmetry and ptosis as variables. Most pairs of breasts are naturally asymmetrical; 
conversely, bra cups are equal in size implying bra size may not be an optimal metric as a 
predictor for radiodermatitis. Liu et al.4 used medical imaging to calculate seven unique 
measurements of the breasts (i.e., nipple level, nipple to midline distance, inferior 
mammary fold level, breast width, breast projection, breast volume, and anterior chest wall 
projection) in 100 Chinese women. They found that 100% of the women had at least one 
of the seven parameters significantly different between the breast pairs.4 An     
investigation by Wood et al.5 in Australia revealed 80% of the study population wore 
incorrectly fitting bras. Moreover, bra cup size may not identify the amount of breast 
ptosis (i.e., drooping). Pendulous breasts increase the surface area in the inframammary 
fold and causes a bolus effect during radiation therapy and predisposes the woman to 
radiation dermatitis.6,7 These issues support the need for a more precise measurement of 
the breast in research studies when breast size is used to predict an outcome such as 
radiation dermatitis. Clinician-measured breast length may provide an answer to this need. 
Hidevegi et al.8 measured the torso surface area of 40 healthy women to estimate 
body surface area in burn victims and found that “for every increase in cup size, the 
surface area of a woman’s anterior trunk increased by a factor of 0.1 relative to her 




may account for 10% of the total body surface area when the bra cup size is greater than 
or equal to DD.8 Using a single measurement of skin toxicity in the breast treatment field 
does not adequately quantify the body surface area impacted by radiodermatitis. 
Although there are several scales used to measure radiation dermatitis, each 
instrument usually employs one global assessment of the breast treatment field to identify 
the maximum level of skin toxicity. However, there is a precedent for making multiple 
assessments of skin toxicity.3,9,10 
Body Mass Index (BMI) 
 
Overweight and obesity are related to increased incidence of breast cancer.1-3,11 
However, they are also known risk factors for the development of radiation 




A strong association exists between smoking during radiation therapy and the 
development of radiation dermatitis.1,3,15-17 Similarly, Fisher et al.18 found a history of 
lifelong tobacco abstinence was associated with a reduction (p = .026) of radiation 
dermatitis development. Smoking tobacco causes vasoconstriction of the cutaneous 
vasculature.19,20 This tobacco-induced vasoconstriction was scientifically measured using 
thermography, laser doppler flowmetry, plethysmography, videomicroscopy, pulse 




Fitzpatrick devised a system describing skin types according to risk of developing 




easily” to “become darker, do not burn.”22 Ironically, skin that is darkly pigmented and 
does not burn but becomes darker is the phototype that often suffers the most severe 
radiation dermatitis.23,24  These findings suggest the need for additional studies to explore 
the use of skin phototype instead of race and ethnicity as a potential predictor of radiation 
dermatitis development. 
 
Nonphysical Sequelae of Radiation Dermatitis 
 
The nonphysical sequelae of radiation dermatitis include treatment delays, early 
termination of treatment, suffering, and lost contributions to the family and society. Bese 
et al.25 found a significant difference (p = .022) in the five and ten year locoregional 
control of breast cancer recurrence in favor of women with treatment interruptions of 0-7 




A feasibility study looks at individual components of a scientific investigation and 
is used to build the foundation of a larger future study26 On the other hand, a pilot study is 
the miniature version of a larger future study.27 The purpose of this study was to 
examine the feasibility of individual measures for a future study, pilot a collection of 
measures planned for use in a larger future study, and provide a scientific estimate of the 
sample size needed for the future study. Our goals were to assess (1) the feasibility of 
eligibility and exclusion criteria, recruitment, retention, refusal, and adherence; (2) 
explore the role of clinician-measured breast length and participant-reported bra cup size 
in the development of radiodermatitis over time on treatment and the efficacy of using 




sizes needed to estimate required sample sizes for future studies. 
 
 
Methods and Materials 
 
This article presents a subset of a broader, longitudinal, mixed-methods pilot 
study on the health-related quality of life of women experiencing radiodermatitis while 
actively receiving external radiotherapy for breast cancer. The first author served as the 
study principal investigator (PI) and single rater of measures and outcomes. Each 





The study was completed at a Comprehensive Community Cancer Program in 
northwestern Illinois. The external treatments were delivered via a Varian Clinac EX 
linear accelerator using 3-dimensional conformal techniques including stand open field, 
hard and enhanced dynamic wedges, and irregular surface compensation. All of the 
patients were treated in the supine position. Thirty-three women received 
normofractionated (i.e., 180-200 cGy) doses and seven women received accelerated 




Thabane’s28 Table 2—Reasons for conducting pilot studies (p. 4) provided a 
framework for assessing the feasibility of our study. The four domains framing our 








Height and weight were measured at baseline, then the BMI was calculated using 
the online Centers for Disease Control and Prevention Adult BMI Calculator.29 
Participant-reported bra cup and band size was recorded. The PI measured the length of 
the affected breast in women who underwent lumpectomy or mastectomy with immediate 
reconstruction. The contralateral breast was measured in women who underwent 
mastectomy without reconstruction. The measurement was standardized by using the 
midclavicular line as a landmark, then measuring the breast length from inframammary 
fold to nipple in centimeters using a 72” disposable paper measuring tape manufactured 
by Medline. 
 
Breast Skin Assessment 
 
The maximum skin toxicity in the radiation treatment field was assessed weekly 
by the PI using the RTOG Acute Radiation Morbidity Scoring Criteria for skin.30,31 
Developed by radiation oncology experts for use in clinical trials with an acute 
radiodermatitis outcome, the RTOG scale includes four ordinal grades of radiation- 
induced skin toxicity including “0” no change from baseline; “1” follicular, faint or dull 
erythema/ epilation/dry desquamation/ decreased sweating; “2” tender or bright 
erythema, patchy moist desquamation/ moderate edema; “3” confluent, moist 
desquamatiom other than skin folds, pitting edema; and “4” ulceration, hemorrhage, 
necrosis.30,31 The PI also assessed the RTOG score for the upper outer quadrant, upper 
inner quadrant, lower outer quadrant, lower inner quadrant, and inframammary fold of 




allow for examination of skin-related quality of life related to specific anatomical sites in 
the treatment field. The RTOG score for these seven areas was summed to provide a total 




The skin phototype was determined by the PI during a short interview with the 
participant. The potential ratings included: type I—always burns, never tans, type II— 
always burns easily, tans minimally, type III—burns moderately, tans uniformly, type 




The radiation treatment plan (i.e., normofractionated, accelerated) was recorded at 
the start of the study. The cumulative radiation dose, energy, fraction number, and use of 




Recommended sample size for pilot studies is a contentious topic and suggestions 
have ranged from 12 subjects per arm to totals of 30 to 50 subjects.32-34 We sought to  
have sufficient power to accurately detect significant differences in our larger pilot study 
looking at the impact of radiodermatitis on skin-related quality of life. Lacking an a priori 
estimate of effect, a sensitivity analysis was conducted using G*Power version 3.1.9.1,35 
with a sample size of 40 participants in one group, .10 alpha level of significance, power 
of .80, epsilon of 1.0, correlation of .50, and six repeated measurements. Using these 




using Cohen’s criteria.36 Since we planned to conduct a descriptive feasibility and pilot 
study, a slightly relaxed level of significance was acceptable in that it help us avoid 




The IBM37 Statistical Package for the Social Sciences Statistics for Windows 
Version 21.0 was used to create a database and analyze the quantitative data collected. 
Means, standard deviations, and ranges were calculated for continuous data; while 
frequencies and ranges were determined for categorical data. A one-way within-subjects 
repeated measures ANOVA was conducted to compare skin toxicity grade of the breast 
using the RTOG scoring system, to compare skin toxicity grade of the breast using the 
RTOG scoring system by each individual area in the radiation treatment field, and the 
total of all scores at baseline and weeks 1, 2, 3, 4, and 5 on external radiation therapy. 
Kendall’s tau is a nonparametric correlation used instead of a Spearman Rho 
correlation  when the sample size is small and there are tied ranked scores (e.g., RTOG 
scores by breast site).38 Therefore, a Kendall’s tau correlation was performed to measure 
the  relationship between factors and the severity of radiation dermatitis at five weeks on 






A purposive sample of 41 English-speaking adult women with stage 0-III breast 
cancer identified as candidates for external beam radiotherapy were accrued to the study 




first week. All of the remaining 40 participants were followed from baseline to 
completion of radiotherapy and completed all study measures. 
One participant had a history of vitiligo. Her depigmented skin did not develop 
radiodermatitis. Her normally pigmented skin reacted similarly to other study 
participants’ skin. Another participant had a history of polycystic ovary syndrome. The 
skin over multiple areas of her body outside of the treatment field was hyperpigmented. 
This participant also had very large breasts, developed grade 3 skin toxicity in the 
inframammary fold, and required a 2-day treatment break. A third participant with very 
large breasts developed grade 3 skin toxicity in the inframammary fold and axilla. She 
required a 9-day treatment break including 4 weekend days. Her skin was examined at 
the predetermined weekly study time points and additional times when she came to the 
cancer center for skin checks. The reported results focus on baseline and five weekly 
observations since seven participants received accelerated treatments and were 
unavailable for follow-up observations. Additional information about the participants is 




Field notes on feasibility and best practices were documented throughout the 
study. Rates on recruitment, refusal, retention, withdrawal, study measures, and 
measurements were calculated. The results of our assessment of feasibility are presented 




Pilot Study Outcomes 
 
A comparison of participant-reported bra cup size and clinician-measured breast 
length is presented in Table 4.3. Participant-reported bra cup size, a new measurement, 
was compared to measured breast length, the current standard measure. Bra cup sizes and 
measured breast lengths were discordant in this study. For example, a woman with a 
breast length of 5 cm reported wearing a C cup ,while another woman with a 6.5 cm 
breast length reported wearing an AA-sized bra cup. Women with 10.5 cm breast lengths 
reported wearing a D, DD, or DDD-sized bra cup. 
A one-way within-subjects repeated measures ANOVA was conducted to 
compare skin toxicity grade of the breast using the RTOG scoring system at baseline and 
weeks 1, 2, 3, 4, and 5 on external radiation therapy. The means and standard deviations 
are presented in Table 4.4. The maximum skin toxicity score significantly increased with 
time on radiation treatment, Wilk’s Lambda = .05 F (5, 35) = 132.07, p <.00001, 
multivariate partial eta squared = 0.95. Overall, 20% of the participants experienced 
grade 1, 75% had grade 2, and 5% suffered grade 3 skin toxicity at five weeks on 
treatment. A one-way within-subjects repeated measures ANOVA was conducted to 
compare skin toxicity grade of the breast using the RTOG scoring system for each 
individual area in the radiation treatment field and the total of all scores at baseline and 
weeks 1, 2, 3, 4, and 5 on external radiation therapy. The means, standard deviations, 
Wilk’s Lambda, F statistic, degrees of freedom, significance level, and eta squared are 
presented in Table 4.5. Skin toxicity significantly increased with time on radiation 
treatment in every site in the radiation treatment field. There was a significant effect size 




smallest effect in the subclavicular area and the largest effect in the axilla. The effect of 
time on the total toxicity score for all areas was η2 = .90, p < .001. 
The relationship between factors and the severity of radiation dermatitis at five 
 
weeks on external radiotherapy of the breast was measured using Kendall’s tau 
correlation. The results are presented in Table 4.6. As expected, there were a number of 
significant correlations between severe radiodermatitis in one area and another area of the 
breast. For example, if radiation dermatitis increased in one breast quadrant, it 
significantly increased in all of the other quadrants, supporting the need for multiple 
measurements of skin toxicity. Radiodermatitis severity in the inframammary fold was 
significantly associated with increased severity in the lower, but not upper breast 
quadrants. 
Race and ethnicity did not have any significant correlations in our nearly all 
White study population. However, as skin phototype (i.e., sunburn resistance) increased, 
radiodermatitis in the inframammary fold also significantly increased (r = .34, p = .02). 
This suggests that skin phototype might be able to discriminate between skin types 
among individuals of the same race. 
With regard to biometrics, as body mass index increased skin toxicity 
significantly increased in the inframammary fold (r = .32, p =.01) and axilla (r = .26, p = 
.05). An increase in bra cup size correlated with an increase in maximum RTOG score at 
five weeks on radiotherapy (r = .29, p = .04), upper medial breast quadrant (r = .29, p = 
.04), lower lateral quadrant (r = .30, p = .02), inframammary fold (r = .41, p = .004), and 
BMI (r = .42, p = .005). Breast length was associated with an increase in in RTOG score 




= .30, p = .02), lower lateral quadrant (r = .30, p = .02); and a highly significant 
association with inframammary fold (r = .45, p = .001), increasing BMI (r = .41, p = 
.002), and bra cup size (r = .57, p = .0003). Overall, breast length had a greater number of 
highly significant correlations. This suggests that breast length may have a stronger 




In this study, we explored the role of clinician-measured breast length and bra cup 
size in the development of radiodermatitis over time on treatment and the efficacy of 




We first studied the feasibility of enrolling women with breast cancer into a 
longitudinal study with weekly assessments of skin toxicity. The women living in our 
community setting were committed to finishing all of the measurements if they elected 
study participation as evidenced by a 98% retention and 18% refusal rate. Our proposed 
measures were feasible in the current study except for the plan to examine the 
development of radiodermatitis by predetermined cumulative radiation doses. Measuring 
radiodermatitis at specific cumulative doses would help control for differences between 
participants that occurs with measurements documented by week on radiotherapy. For 
example, participants frequently start and complete radiotherapy on various days of the 
week and different doses may be prescribed. However, we were not able to measure skin 






We piloted two measures that could improve the ability to predict or measure skin 
toxicity. Accurately identifying risk factors for breast radiodermatitis is important for 
studies of measures that may prevent or manage that toxicity. 
The current study demonstrated a number of significant findings. As expected, the 
maximum skin toxicity (i.e., RTOG) score significantly increased with time on 
radiotherapy and the mean score at five weeks on radiotherapy was 1.85. Moreover, skin 
toxicity significantly increased with time on radiotherapy in every site in the radiation 
treatment field. More importantly, by implementing multiple assessments of skin toxicity, 
our results showed a mean RTOG score of more than 1.0 in all areas of the treatment 
field, 1.58 in the inframammary fold, and 1.60 in the axilla at five weeks on radiotherapy. 
A grade 1 acute skin toxicity may include dry desquamation, while grade 2 may include 
patchy moist desquamation and is considered a moderate to severe toxicity.39 
The mean of the summed RTOG scores for all seven sites in the treatment field 
 
was 8.85, much higher than a single measurement of the maximum skin toxicity. 
Assessing dermatitis in multiple areas within the radiation treatment field can be 
performed quickly when the data is inputted into a standardized form. While the clinical 
significance of the summed RTOG scores remains to be determined, these multiple 
measurements may provide increased sensitivity to small but clinically significant 
subjective changes in radiation dermatitis during studies to test potential interventions. 
Additionally, use of multiple measurements can allow for a scientific comparison of the 
efficacy of interventions in one site in the treatment field versus another site. For 






We proposed the concept of clinician-measured breast length for this feasibility 
study because studies have shown that bra cup size is not a reliable proxy for actual 
breast size. As illustrated in Table 4.3, participant-reported bra cup size was discordant 
with clinician-measured breast length, which is a more scientific alternative to 
participant-reported bra cup size. Breast length was significantly positively correlated 
with radiodermatitis in the inframammary fold and upper medial, upper lateral, and lower 
lateral breast quadrants in this study. Similarly, Porock et al.1 found bra cup size greater 
than size C predicted an RTOG skin toxicity score of 2 or higher in the inframammary 
fold, upper outer quadrant, upper inner quadrant, lower outer quadrant, and lower inner 
quadrant of the breast radiotherapy treatment field. Pires, Segreto, and Segreto40   
measured breast height (i.e., distance from the chest wall to nipple measured on a contour 
plan), and found that each centimeter of increased height increased the chance of 
developing grade 3 skin toxicity by 2.61 fold. Overall, these findings support the 
importance of breast size as a risk factor for radiodermatitis. 
Measuring the breast length takes only a few seconds and is not costly disposable 
measuring tapes are inexpensive (e.g., 15 cents each in our study) and the measurement 
can be completed by a registered nurse or trained research associate. Conversely, breast 
volume calculation by a radiation oncologist or medical physicist on a contour plan is a 
more expensive alternative to clinician-measured breast length. To provide a context, 
Caruso, Guillot, Nguyen, and Greenway41 compared the cost of using a manual 
measurement of breast volume (i.e, Grossman Roudner breast-measuring device, breast 




breast size after application of topical compounds as an alternative to breast augmentation 
surgery. Use of  MRI was 373 to 33,500 times more expensive than the manual method  
of measuring breast volume. 
Clinician-measured breast length may prove an effective predictor of 
radiodermatitis instead of, or in addition to, participant-reported bra cup size. However, 
evidence regarding the comparative effectiveness of clinician-measured breast length, a 
new measure, versus participant- or client-reported bra cup size, the current standard, is 
still needed.42 
Strengths and Limitations 
 
There are a number of strengths of this study. For example, accrual goals were 
met. There was only one rater of skin toxicity eliminating the issue of interrater 
reliability. However, threats to intrarater reliability include fatigue, time of day, 
attention.43 Each woman served as her own control eliminating between subjects 
variance. We tested and reported the feasibility of our measures planned for use in future 
studies. 
 
Study limitations include a small sample size with limited diversity. We hoped to 
examine skin toxicity by severity and site using cumulative radiation dose as the factor. It 
was not feasible to track the participants throughout the course of radiation therapy to 







This pilot and feasibility project enabled us to identify several recommendations 
that will be important in similar future research studies. For example, performing 
assessments on Mondays allowed for follow-up on Tuesday through Friday to collect 
missing information for a given week. Ideally, future investigators or research staff 
should be onsite on a daily basis to facilitate recruitment and collection of time-sensitive 
data. Our data collection form for seven areas in the breast radiation treatment field 
worked well but might be improved by adding an image of the posterior surface of the 
chest. Creating a form with an image of mastectomy without reconstruction (i.e., chest 
wall) would also aid in mapping radiodermatitis. 
Additional studies are needed to determine the clinical significance of the total 
RTOG score for all areas in the radiation treatment field. The utility of clinician-measured 
breast length and multiple measurements of skin toxicity in the treatment field must be 
tested in larger studies and more diverse populations. However, it was feasible  to 
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Sample Characteristics (n = 40) 
 
 





Nipple-to-fold breast length in cm 
Mean (Range) 59 (40-82) 
SD 11.63 
Mean (Range) 29 (18.0 -52.9) 
SD 8.04 










 A 2 ( 5) 
 B 6 (14) 
 C 16 (40) 
 D 7 (17.5) 
 DD 4 (10) 
 DDD 1 ( 2.5) 
 J 2 ( 5) 
 
Bra band size 












 Previous smoker 19 (47.5) 







 Asian 1 ( 2.5) 
Skin phototype    
 I 8 (20) 
 II 11 (27.5) 
 III 11 (27.5) 
 IV 5 (12.5) 












 I 7 (17) 
 IIa 15 (36) 
 IIb 3 ( 7) 
 IIIa 4 (10) 
 IIIb 2 ( 5) 
 
Grade 
IIIc 2 ( 5) 
 1 6 (15) 












 Lobular 5 (12.5) 
 DCIS 7 (17.5) 






 PR positive 30 (75) 
 
Surgery 
HER2 positive 9 (22.5) 
Lumpectomy 28 (70.0) 
Mastectomy with reconstruction 5 (12.5) 
Mastectomy without reconstruction 6 (15) 
None 1 ( 2.5) 
Systemic therapy (yes) 
 
Chemotherapy 22 (55) 
Hormone therapy 0 ( 0) 
Trastuzumab 6 (15) 











Recruitment Recruitment was most successful on the consultation day, 
moderately successful at the simulation visit, and least 
successful just prior to treatment on the first day of therapy. It 
took 13 months to recruit our participants. 
What was the refusal rate? 18% (9 of 50 potential participants declined participation) 
Can the refusal rate be 
decreased without 
coercion? 
The most frequent reason for refusal was “overwhelmed right 
now.”  One woman perceived participation in any study as 
highly experimental and “beyond imagination.” 
What was the retention rate? 98% (Only 1 of 41 participants who consented withdrew) 
Can the retention rate 
be improved? 
Eligibility criteria: 
Are there any problems 







Are there any problems 
with the instruments? 
All participants who remained in the study beyond the baseline 
time point completed all of the measures 
 
Recommend including women with inflammatory breast cancer 
who are post-mastectomy 
Recommend including males and transgender females with 
breast cancer 
Recommend including individuals with certain conditions 
affecting skin pigmentation such vitiligo and polycystic ovary 
syndrome 
 
The income range on the demographics form should extend 
higher than $75,000 per year 
Create a breast skin assessment form with a mastectomy image 
Consider adding an image of a back on the breast skin 
assessment form 
RTOG Acute Radiation Morbidity Scoring Criteria does not 




Determine capacity and 













Does the center adhere 
to promises? 
Assessing for skin toxicity in the treatment vault during set-up 
for treatment prevented the need to use an exam room and 
saved the participant from needing to undress for the study 
Investigator having a pre-existing working relationship with the 
radiation oncology team enhances trust and cooperation 
Conducting study assessments every Monday worked well in a 
department operating Monday-Friday.  This allows 4 days in a 
row to capture any missed assessments since many radiation 
oncology departments operate on a Monday through Friday 
basis 
On rare occasions, patients would request a one-time change in 
appointment time.  The PI was not informed of these changes 
since she was not employed at the cancer center and this led to 
missed assessments requiring extra trips to the cancer center. 








What qualifications are 
needed by the PI? 
 
Are there improvements 
needed to enhance 
management of the study? 
Researcher needs to be familiar with and work in radiation 
oncology department, and have dedicated time for the study 
(e.g., all study measures, data management). 
Scannable data forms would likely enhance data accuracy 
and save time 
 
Scientific Findings/Recommendations 
Can effect sizes be 
calculated and to which 
populations do they 
apply? 
Calculating effect sizes (ES) to inform future power 
analyses is helpful.  Care must be taken to avoid over- 







Comparison of Participant-reported Bra Cup Size and Clinician-measured Breast Length 
 
Bra Cup Size n Breast Length in cm (range) 
AA 1 6.5 
A 2 5.0-7.0 
B 6 6.0-8.0 
C 16 5.0-12.5 
D 7 7.5-10.5 
DD 4 10.5-19 
DDD 1 10.5 
J 2 14.0-15.0 






Descriptive Statistics for Radiation-induced Skin Maximum Toxicity of the Breast at 
Baseline and Weeks 1 to 5 on Radiotherapy*   
 
Time Period n  M SD 
Baseline (before RT)  40 .00 .00 
Week 1 on RT  40 .10 .30 
Week 2 on RT  40 .60 .67 
Week 3 on RT  40 1.08 .69 
Week 4 on RT  40 1.45 .55 
Week 5 on RT  40 1.85 .48 
Abbreviations: RT = Radiotherapy, n = number of participants assessed, M = 
mean,  SD = standard deviation 
*The RTOG Acute Radiation Morbidity Scoring Criteria-Skin was used to measure 
maximum skin toxicity. The ratings range from “0” no change over baseline; “2” 
tender or bright erythema, patchy moist desquamation/ moderate edema; “3” 
confluent, moist  desquamatiom other than skin folds, pitting edema; and “4” 









Summary Table for Within-subjects Repeated Measures Analysis of Variance of Radiodermatitis of the Breast by Site in the Treatment 
Field 
Time M SD Wilkes λ F DF* p η2 




.23 23.90 (5,35) <.001 .77 
Week 1 .03 .16      
Week 2 .13 .40      
Week 3 .50 .68      
Week 4 .68 .73      
Week 5 1.18 .68      
Upper Lateral Quadrant  .16 35.72 (5,35) <.001 .84 
Baseline .00 .00      
Week 1 .05 .22      
Week 2 .25 .54      
Week 3 .65 .70      
Week 4 .70 .69      
Week 5 1.23 .62      




.18 32.87 (5,35) <.001 .82 
Week 1 .03 .16      
Week 2 .23 .48      
Week 3 .63 .67      
Week 4 .80 .79      
Week 5 1.13 .61      
Lower Lateral Quadrant  .16 37.07 (5.35) <.001 .84 
Baseline .00 .00      
Week 1 .08 .27      
Week 2 .15 .36      
Week 3 .73 .68      
Week 4 .95 .78      














Table 4.5 Continued 




Baseline .00 .00 .12 66.97 (4,35) <.001 .88 
Week 1 .00 .00 
Week 2 .23 .48 
Week 3 .78 .66 
Week 4 1.25 .67 
Week 5 1.58 .64 
Axilla 
Baseline .00 .00 .11 56.57 (5,35) <.001 .89 
Week 1 .03 .16 
Week 2 .15 .36 
Week 3 .43 .71 
Week 4 .93 .69 
Week 5 1.60 .59 
Subclavicular Area 
Baseline .00 .00 .40 10.60 (5,35) <.001 .60 
Week 1 .03 .16 
Week 2 .28 .55 
Week 3 .48 .75 
Week 4 .65 .74 
Week 5 1.00 .85 
Total for all Sites .10 65.22 (5,35) <.001 .90 
Baseline .00 .00 
Week 1 .23 .86 
Week 2 1.40 2.04 
Week 3 4.08 3.34 
Week 4 5.95 3.65 
Week 5 8.85 3.08 
















Variables Related to the Severity of Radiation Dermatitis at Week 5 among Women Receiving Breast Radiotherapy 
 
 Measure 1 2 3 4 5 6 7 8 9  10  11  12 
1 RTOG                













































































        
9 Skin                
 Type .18 .18 .18 .19 .09 .34* .21 -.02        
10                 
 BMI .15 .15 .13 .13 .22 .32* .26* -.05 -.06       
11 Bra Cup                
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The purpose of this pilot study was to begin the validation process for using the 




Participants completed the DLQI instrument weekly while receiving external 
radiotherapy of the female breast. At week five on treatment, 31 (78%) participants 
provided narrative feedback on how each DLQI item impacted her life. Agreement 
between the DLQI numerical ratings and the narrative feedback was assessed. Construct 
validity was estimated using principal component analysis (PCA). Reliability of the 




Agreement between DLQI ratings and narratives ranged from .71 to .98. The 
DLQI work and study subscale was removed from our analyses because the variance was 
zero. PCA supported the inclusion of all of the remaining subscales. The remaining DLQI 




The results of our examination of the DLQI when used for breast radiodermatitis 






A majority of women receiving external beam radiotherapy for breast cancer 
experiences radiation skin changes.1 The current standard of care in radiation oncology is 
to describe the physical attributes of radiodermatitis as a skin toxicity. Although this is 
important, it does not address the patient’s personal experience. The results of previous 
studies have demonstrated that women receiving external beam radiation therapy for  
breast cancer experience significant alterations in health-related quality of life (QOL). For 
example, Pignol et al.2 found a highly significant correlation between the  development of 
moist desquamation, an increase in reported breast symptoms (p = .0028)  and pain score 
(p < .0001). Women actively receiving external beam radiation therapy for breast cancer 
in a study by Miller et al.3 reported experiencing itching, burning,  stinging, pain, 
irritation, embarrassment, depression, decreased social interaction, and  diminished ability 
to show affection. The profound effect radiation dermatitis has on  quality of life causes 
some women to withdraw from treatment.4 Radiation dermatitis is  related to a 
constellation of physical factors such as radiation-induced skin changes,  inflammatory 
responses, and genetic endowment.5,6 Further, these physical factors  directly impact 
quality of life among women receiving external beam radiotherapy for invasive breast 
cancer. Schnur et al.7 found a relationship between season of the year and  amount of skin 
bother. 
To help remedy the dilemma of radiodermatitis impact on quality of life, a 
scientifically and independently validated instrument to measure skin-related quality of 
life among patients receiving radiation therapy is needed. The Dermatology Life Quality 




dermatologic conditions including eczema.8 Eczema is somewhat similar to radiation 
dermatitis since it causes itching, erythema, edema, and moist desquamation.9.10 However, 
the DLQI has not been formally validated for use in radiodermatitis. We  sought to begin 





This report describes a subset of a larger study. A purposive sample of women 
about to undergo external breast radiotherapy was recruited at a Midwestern cancer 
program in a community setting. 
Baseline measures were completed, then the women were followed throughout 
radiotherapy. Skin-related quality of life data were collected two survey instruments (i.e., 
DLQI, radiation skin changes form). Participants completed the DLQI at baseline and 
each week while on radiotherapy during the main study. At the fifth week on 
radiotherapy, the participants were asked to provide written feedback on how the 
Dermatology Life Quality Index (DLQI) items impacted their lives. This feedback was 




There are many components in the process of validating an instrument.11 Each 
process measures a different aspect of the instrument’s strengths or weaknesses. We 
estimated the concurrent, content, construct validity, and reliability of the DLQI among 




Concurrent Validity and Informant Agreement 
 
Concurrent validity focuses on the extent to which a measure such as the DLQI 
adequately reflects the individual’s perspective on a criterion.12 We measured the 
concurrent validity of the DLQI by assessing the agreement of participant informant’s 
responses on the DLQI and their narrative responses to a survey about the DLQI, both at 
five weeks on radiotherapy. Informant agreement was measured at five weeks on 
treatment when skin toxicity begins to peak. An extra copy of the DLQI and the only 
copy of the radiation skin changes form were given to the participant. Each woman was 
instructed to look at the extra copy of DLQI. Next, participants were invited to write 
narratives about how each item on the DLQI impact their life. Thirty-one (78%) of the 40 
participants provided narratives. The principal investigator (PI) abstracted the week five 
DLQI responses and the narratives on impact. The data were entered into a form with a 
column for the ordinal score on the DLQI (i.e., very much, a lot, a little, not at all), a 
column for a verbatim copy of the narrative, and a column for researcher rated level of 
agreement. Three researchers jointly coded the agreement score (i.e., agree, disagree) for 
each DLQI participant rating and narrative for the first participant. Subsequently, each 
researcher coded her perceived level of agreement for the remaining participant responses 
independently. The PI combined the agreement ratings by each researcher into one master 
document. The document was shared with each researcher, the agreement ratings were 
discussed and consensus formed for items on which the agreement ratings did not 
originally agree. Percent agreement was calculated by dividing the total number of 
participant responses for each DLQI item by the number of paired responses where the 






Content validity focuses on whether the instrument represents the domain of 
interest.12 In this study, it was assessed by soliciting feedback on the DLQI from expert 
12 radiation oncology nurses at a chapter meeting of the Oncology Nursing Society. A 
hard copy of the DLQI was given to each nurse. The nurse was instructed to read the 




Construct validity focuses on the extent that items on a measure such as the DLQI 
are consistent with the concept of interest.12 It was assessed using principal component 
analysis (PCA) of the DLQI subscales. A variety of participant per factor ratios are 
suggested in the professional literature, ranging from 3 to 15 participants for each 
factor.13-17 We had 40 participants and five subscales yielding a ratio of 8:1. Our sample 
size adequacy was also estimated post hoc by examining the Kaiser-Meyer-Olkin (KMO) 
statistic and communalities after extraction, both with values greater than 0.5 if the  
sample size is adequate.18 The work and study subscale was removed during analysis from 




The reliability of the DLQI subscales was assessed using a Cronbach’s alpha 
analysis and examining the interitem correlations. An alpha of 0.7 or higher and inter- 
item correlation of 0.3 or greater was considered acceptable.18 Again, the work and 






The IBM Statistical Package for the Social Sciences (SPSS) Statistics for 
Windows Version 21.0 was used to analyze our quantitative data.19 Principal component 
analysis and direct oblimin rotation were used to examine the loading of the DLQI 
subscales. Cronbach’s alpha was used to examine the internal consistency of the DLQI. 
 
Human Research Subjects Protection 
 
This study was approved by the University of Utah Institution Review Board 
(UIRB). A reliance agreement was created between the UIRB and the health care system 
affiliated with the cancer program. Each woman provided her consent to participate in the 
study. Only the principal investigator had access to participants’ personal health 
information. A unique participant identification number was assigned to promote 
anonymity and confidentiality with other investigators. This number was used to link all 




Sample of Participants with Breast Cancer 
 
Thirty-one of the 40 participants in the main study provided usable narrative 
responses about the DLQI items. All 40 participants were female with stage 0 to III breast 
cancer. They ranged in age from 40 to 82 years with a mean age of 58 years. The typical 
participant was non-Hispanic White (97%), had some level of college education (74%), 
worked in a professional occupation (42%), earned more than $75,000 annually (45%), 
was normal weight (39%) or obese (39%), and did not currently smoke (94%). See Table 





Concurrent Validity/Informant Agreement 
The percent of agreement between participant ranked responses on the DLQI and 
narrative responses on the radiation skin changes form ranged from 71% to 98%. See 
Table 5.1. There is no established standard for acceptable informant agreement. However, 
Graham, Milanowski, and Miller20  suggest using a range of 75% to 90% absolute 
agreement as a measure of interrater agreement. Our results closely  parallel that range. 
The first item on the DLQI inquires about three sensations (i.e, pruritis, pain, 
stinging) and had the lowest level of agreement. The respondent needed to mention these 
three sensations to meet the requirements for agreement. The item that focuses on sports 
had the highest level of agreement. However, most participants responded that their skin 





The radiation oncology nurses did not recommend the addition or deletion of any 
DLQI items. They suggested a few minor word changes. For example, “not relevant” 
might be changed to “does not apply.” We found the content validity of the DLQI 




Our KMO statistic was .68 and the communalities ranged from .68 to .92, 
indicating a sufficient sample size to complete a PCA [18]. Bartlett’s test of sphericity 




large for PCA. Correlations between the DLQI subscales were calculated and were 
greater than or equal to .3. See Table 5.2 for additional information. All of the subscales 
focused on skin-related QOL and were likely correlated. Therefore, a direct oblimin 
rotation was implemented.17 The rotated DLQI subscales, sans the work and study 
subscale, loaded exclusively on one of two components that together explained 83% of 
the total variance in the analysis, supporting the retention of these subscales. Subscales 
that clustered on component one include daily activities, leisure, and personal 





The work and study subscale was removed from analysis because the variance  
was zero. The DLQI remaining subscales demonstrated good internal consistency, α = .84 
and were worthy of retention. The greatest increase in alpha would come from deleting  






No skin-related quality of life instruments independently validated for use in 
radiation dermatitis were found. As a result, we remain unable to effectively assess the 
usefulness of topical agents that could decrease suffering, prevent treatment delays or 
early termination, and improve quality of life for thousands of breast cancer patients. By 
improving our approach to the assessment of radiation dermatitis and quality of life 




this problem. One potential solution includes using a quality of life instrument 
specifically designed for skin conditions (i.e., the Dermatology Quality of Life Index) to 
improve assessment of patient perception of quality of life during the presence of 
radiation dermatitis. We sought to begin validity and reliability assessment of the DLQI 
when used to measure skin-related QOL among women experiencing breast 
radiodermatitis in this pilot study. The DLQI’s performance was not perfect, but was 
acceptable in our pilot study. Further studies are needed to continue the validation of the 
DLQI for use in breast cancer radiodermatitis. 
The overall validity and reliability of the DLQI in our pilot study was good. The 
percent informant agreement between the DLQI ratings and narrative comments was 
respectable, ranging from 71 to 98%. Upon assessing the content validity of the DLQI, 
radiation oncology nurses suggested a few small changes in the wording of the DLQI. 
However, changing the DLQI would alter its established reliability and validity.21 
Additionally, this instrument is copyrighted and its authors will not permit changes.22 The 
variance between our participants on the DLQI work and study subscale was zero and  
was removed from our statistical analyses. An estimate of construct validity using PCA 
with a direct oblimin rotation supported the remaining DLQI subscales. The reliability of 
the remaining subscales demonstrated good internal consistency with α = .84. Similarly, 
the creators of the DLQI reported a Cronbach’s alpha of 0.83 when used for dermatologic 
conditions.6 
 
Seasonality, the predictable effects of calendar-related fluctuations in weather 
condition (e.g., cold weather during winter, hot weather during summer)23 influenced 




participated during summer months commented about needing to cover up and avoid sun 
exposure to radiated areas. Embarrassment was an issue because summer clothes are 
more revealing than winter clothes. Conversely, winter participants commented that 
clothing was not an issue because everyone is bundled up. Schnur et al.7  found similar 
findings in a study of breast radiodermatitis; in addition to avoiding sun exposure and 
covering skin changes from view, their study participants reported issues with body odor 
related to radiodermatitis being an issue during the summer. Seasonality also impacted 
our participant’s responses to the question about sports. Women that liked to golf were 
bothered if receiving treatment during the summer, but not if treatment was scheduled in 
the winter. These findings suggest that the results studies focusing on skin-related QOL 
may be influenced by the season when data are collected. 
 
Strengths and Limitations 
 
One strength of this study is that it can serve as a pilot for future, larger studies. 
 
Our sample size was modest, yet statistical testing for adequacy of sample size suggests it 
was large enough for a pilot study. Caution must be taken regarding applying our results 
to other populations with greater diversity and living outside of community settings in the 
Midwestern U.S. since this was a single site pilot study. Because the work and study 
subscale was removed from our PCA and alpha Cronbach’s analysis, it is inappropriate to 




Breast radiodermatitis has a profound impact on quality of life. Additional larger 




radiodermatitis on work and study needs further exploration. Since the variance in the 
work and studying subscale was zero, we are curious to learn whether this phenomenon is 
common among breast cancer patients receiving radiotherapy. Also, seasonal effects must 
be considered for longitudinal studies or when study accrual extends across seasons in 
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Agreement between Participant Scored Ratings on the DLQI and Narratives of the 
Radiation Skin Changes Form 
 
(n = 31) 
%* 
  Agreement   
Symptoms & Feelings Subscale 
1. Over the last week, how itchy, sore, painful or 71 
stinging has your skin been? 
2. Over the last week, how embarrassed or self 87 
conscious have you been because of your skin? 
Daily Activities Subscale 
3. Over the last week, how much has your skin 74 
interfered with you going shopping of looking after your 
home or garden? 
4. Over the last week, how much has your skin 90 
influenced the clothes you wear? 
Leisure Time Subscale 
5. Over the last week, how much has your skin affected 87 
any social or leisure activities? 
6. Over the last week, how much has your skin made it 98 
difficult for you to do any sport? 
Work & School Subscale 
7. Over the last week, has your skin prevented you from 97 
working or studying? 
Personal Relationships Subscale 
8. Over the last week, how much has your skin created 74 
problems with your partner or any of your close friends 
or relatives? 
9. Over the last week, how much has your skin caused 97 
any sexual difficulties? 
Treatment Subscale 
10. Over the last week, how much of a problem has the 74 
treatment for your skin been, for example by making 
  your home messy, or by taking up time?   






Measures of Reliability and Validity for the Dermatology Life Quality Index 
(DLQI)  Subscales in Breast Radiodermatitis 




Correlation with Alpha if subscale Component 
other subscale  is removed  1 
Component 
2 
  items   
Symptoms & .62 .81 
Feelings Subscale 
Daily Activities .67 .80 
Subscale 








Work & School Had zero variance and was removed NA NA 
Subscale from the scale during principal 
component analysis in SPSS 
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Little is known about skin-related quality of life among women receiving external 




The aim of this pilot study was to describe the thoughts and experiences of 





A printed survey was used to solicit feedback on the Dermatology Life Quality 
Index (DLQI) during the fifth week of external radiotherapy. An open-ended question 
inquired which DLQI-related issue was most important and why. A content analysis was 




Twenty-eight women provided a response to the “most important” question. Sixty 
narratives led to the identification of 35 codes and six themes during content  analysis. 
Themes included perspectives on having radiodermatitis, sensations caused by 
radiodermatitis, knowledge and preparation for radiotherapy, prevention of 







The results of this study provide a glimpse into the perceptions of skin-related 
quality of life in breast cancer patients who received external radiotherapy in a 
community setting and experienced radiation dermatitis. Some women expressed that 
radiodermatitis had profound impact on their quality of life while other were surprised 
that radiation therapy was easy compared to chemotherapy. 
 
Implications for Practice 
 
Our findings parallel those found in a previous study conducted in an urban 
setting. The results provide insight into the thoughts and needs of women undergoing 
external radiotherapy of the breast. Assessing individual differences in skin-related QOL 
can provide can provide needed information for tailoring care to the unique needs of each 





“I hope she does better than I did. I got all burnt up!” commented the daughter of 
a woman with breast cancer who was about to start radiation therapy. The daughter was 
also a breast cancer survivor. Her haunting comment inspired our study. 
Radiation dermatitis is a treatment-induced dose-limiting toxicity.1 The National 
Cancer Institute defines radiation dermatitis as “a skin condition that is a common side 
effect of radiation therapy. The affected skin becomes painful, red, itchy, and blistered."2 
Radiodermatitis can lead to treatment delay or early termination, lost work productivity, 




greatly impact quality of life.3,4 
 
Three previous studies strongly informed our investigation. While many 
interventional studies designed to explore the efficacy of products created to prevent or 
manage radiodermatitis also examine skin-related quality of life as a secondary outcome, 
to date, only one pilot and one larger study were found that focus exclusively on skin- 
related quality of life in breast cancer patients receiving radiotherapy. Schnur et al.4 
conducted a pivotal qualitative study using a semistructured guide to conduct in-depth 
interviews of women with breast radiodermatitis at an urban major medical center that 
focused on women’s experiences of skin changes during radiation therapy and how those 
skin changes impacted the women’s lives. In an earlier study, Schnur et al.5 had 15 
women keep a diary of their experiences during breast radiation therapy in a pilot study. 
The findings of both studies will be compared with and contrasted against our results. 
A study by McMullen et al.6 also influenced the design of our pilot investigation. 
 
These researchers conducted a mailed survey study on challenges encountered by 
survivors of colorectal cancer with a stoma for at least five years. They included an 
opened-ended question at the end of the survey that asked the participant to share the 
greatest challenge encountered related to having an ostomy and used a qualitative 
approach to analyze responses to the greatest challenge question. 
Most cancer research studies are conducted at major medical centers in urban 
locations. These settings have access to large populations that when sampled supply 
enough power to answer important research questions. However, only 15% of cancer 
patients receive cancer treatment at urban major medical centers; the remaining cancer 




research and explore the perspectives of women with breast cancer in these community 
settings. Environmental factors such as proximity to the cancer program and access to 
transportation may differentially influence the perspectives of urban-dwelling versus 
community-dwelling breast cancer patients. Our primary aim was to describe the 
thoughts and experiences of women experiencing radiation dermatitis of the breast at a 
cancer program in a community setting. 
 
Design and Methods 
 
A qualitative analysis of study participants’ written responses to an open-ended 
survey question is presented in this article. This analysis is part of a larger, longitudinal, 
mixed-methods pilot study on the skin-related and global quality of life among women 
experiencing acute radiodermatitis of the breast in a community setting. For one portion 
of this pilot study, we used a survey to seek feedback from participants regarding the 
impact and adequacy of each item on the Dermatology Life Quality Index (DLQI) at five 
weeks on external radiotherapy. All aspects of the study were designed to cause minimal 
intrusiveness and burden for the participants who were actively receiving radiation 
therapy. Similar to McMullen et al.,6 we included an open-ended question at the end of 
the survey. This article presents the results of a content analysis on the responses to that 
question. 
 
Human Subjects Protection 
 
The study was approved by the University of Utah Institutional Review Board 
(UIRB). A reliance agreement was created between the UIRB and the health care system 




used on each study form to identify the participant to enhance maintenance of 
confidentiality. 
 
Participants and Setting 
 
A purposive sample was recruited from a Comprehensive Community Cancer 
Program located in a United States Census Bureau designated “urban cluster” from May 
2014 to April 2015. An urban cluster is an area with a population of more than 2 500 and 
less than 49 999 individuals.8 The catchment area for this cancer program is northern 
Illinois and southern Wisconsin including a vast rural area. Eligible participants included 
English-speaking females aged 18 years or older with stage 0-III breast carcinoma that 
had not started, but were recommended to receive external radiotherapy of the whole 
breast. Additional details about the sample are provided in Table 6.1. A radiation 
oncologist identified each woman as a candidate for external radiotherapy of the breast. 
The first author invited each potential participant to join the study and collected informed 
consent from each woman who accepted the invitation. Forty women participated in the 
main study and were asked to complete an open-ended survey about items on the 
Dermatology Life Quality Index instrument.9 The last question on the survey inquired, 
“Which issue is most important and why?” Of the 40 main study participants, 28 




The survey was provided in hard copy at the fifth week on radiation therapy when 
radiodermatitis was likely to begin to peak. The participant was asked to complete the 




verbatim into a single digital text file by the first author. The digital file was stored on a 
secure, password protected, encrypted external drive. The hard drive was locked in a 




Our goal was to gain a greater understanding of patient-reported skin-related 
quality of life in the presence of breast radiodermatitis. A qualitative content analysis 
approach was implemented. This research method uses a flexible yet systematic 
classification process of coding and identifying themes to permit the subjective 
interpretation of the content of data.10 This systematic approach helps to ensure the 
reliability and replicability of the results.11 
Each member of the investigative team independently reviewed all of the 
 
comments. A list of initial codes was generated during telephone conferences and via 
email conversations. The first and second author independently assigned codes to the  
data. The responses were divided to represent one unique concept. None of these concepts 
were assigned more than one code. The third author reviewed the coded data and  
provided input. The results were discussed and consensus was reached. The first author 
reviewed the coded data to identify final codes and overarching themes. Since the 
participant was completing a survey about the 10 items on the DLQI, the six conceptual 
domains of this instrument (i.e., symptoms and feelings, daily activities, leisure, work and 
school, personal relationships, and treatment) influenced participant’s responses and 






Six themes were identified during data analysis: perspectives on having 
radiodermatitis, sensations caused by radiodermatitis, knowledge and preparation for 
radiotherapy, prevention of radiodermatitis, emotions induced by skin changes, and 
physical appearance of the breast skin. Numerical counts and percentages of codes were 
calculated to help elucidate the frequency of these concerns among the participants and 
are provided in Table 6.2. 
 
Perspectives on Having Radiodermatitis 
 
The participants described their perspectives regarding the experience of having 
radiodermatitis of the breast along a dynamic and vast continuum. Some women 
expressed a positive attitude regarding cancer care. 
-I feel very lucky and fortunate that my cancer was found early and has not 
spread  yet. Also, I know there are many women who are not as fortunate in 
their diagnosis and those whom have much worse reactions to radiation. 
-The treatment is a little uncomfortable but if it is increasing my chances of not 
having a recurrence of cancer, it been just a small price to pay. 
Cancer care often encroached on pre-existing plans for summer vacations, travel, 
school, work, and family reunions. A number of women expressed having a deadline in 
mind when all aspects cancer care would be completed. 
-I don’t want to delay my “exchange” with the plastic surgeon. I didn’t expect 
to  have radiation at all so I’m months behind my schedule to get on with my 
life. 




effects were expected to appear and to resolve. One lady commented, “This is taking too 
long to recover. . . I’m not going to do any more [radiation]” (p. 671).4 Another woman 
wondered whether her breast would stay red and sore forever.4 
 
Sensations Caused by Radiodermatitis 
 
Thirty-two percent of the participants wrote about the physical sensations that 
accompany radiodermatitis of the breast. Itching, pain, and tenderness were the most 
commonly reported sensations. 
-For me, the extreme itchiness has been the most important issue. I have been 
concerned and sometimes upset, because I have been unable to get consistent 
relief. Although I have continued with my regular activities and what I want to 
do, the itchiness was always ‘there’—difficult to completely ignore or forget. 
And, although I realize my skin did not get this way overnight and will take 
time to heal, I have been concerned at how long that will actually be. 
- The soreness and redness hurts and keeps me from doing some things 
that I usually do. Not a big problem but it’s a constant reminder of what is 
and has happened to me. 
- The only issue of importance to me is my comfort level with the clothes I 
wear. This is nothing really new—wool has always itched, cashmere, silk, 
and fabric that does not breathe causes claustrophobia; polyester makes me 
sweat—‘yes,  cotton is the fabric of my life’ says the advertising. 
-I feel like a grease monkey! 
 
-It feels like I am boiling inside of my breast. 
 




Emotions Induced by Skin Changes 
 
Some women in our study were open about expressing their emotions about 
radiation dermatitis while others hid their emotions and needs, embracing stoicism. 
- How it looks like depresses me. 
 
- I keep it in. No one knows the pain I have unless I am asked about it—and 
then I say ‘I’m ok.’ 
In the study in 2009 by Schnur et al.,5 one woman wrote her diary that since she could see 
the radiation skin changes, she knew “they’re aiming right” (p. 672). Other women 
verbalized perceptions that since radiation therapy is invisible, they wondered if the 
treatment was being administered correctly or whether it would work.5 A participant in the 
present study expressed a related concern. 
-I am also concerned of what the radiation does to me. I know it’s to kill the 
cancer but it’s scary how it destroys the good tissues too. I am looking forward 
to the treatments being over and my body healing itself back to normal. 
Many women in our study eagerly anticipated finishing radiation therapy. For most 
women, completion of radiation therapy heralds the end of nearly a year of cancer 
therapy. 
-I am anxious to have the side effects of radiation behind me so I am faithful in 
caring for my skin. 
In addition to emotions directly related to skin toxicity, it is important to 
consider  the impact of issues occurring in the patient’s life outside of the cancer 
experience. Two  participants were widowed while receiving chemotherapy a few 




- I have bigger things to worry about! I lost my husband not long ago! 
 
One recently divorced woman needed to hold two job positions during breast cancer care. 
Many women needed to schedule their radiation therapy appointment at 7-7:30 am (i.e., 
before the cancer center officially opened) to avoid tardiness and potentially losing their 
daytime employment. One woman worried about her husband who was affected by 
Alzheimer disease wandering away while she was in the radiation treatment vault. 
Another was reluctant to receive radiotherapy because she needed to babysit her 
grandchildren so that her daughter, a single mother, could work. 
 
Physical Appearance of the Breast Skin 
 
Only five women expressed concerns about the physical appearance of their 
breast or skin. This was a very important issue for some women. For example, a 
participant wondered if her affected breast would ever look normal again. She previously 
had a breast reduction surgery years prior to her breast cancer diagnosis to improve the 
look of her breasts. Conversely, another woman was surprised to complete radiation with 
minimal skin toxicity and bother. 
-You should ask how the coloring of your skin is. How that affects you . . . 
You don’t ask if it is cracking, dry, bleeding—how the skin is. Are the creams 
helping? 
-I have not experienced most of the effects I was expecting. I have what 
amounts to a mild sunburn so far. 
A woman in the study by Schnur et al.4 in 2011 commented that dermatitis was worse 
than a sunburn because sunburn goes away but dermatitis “just keeps getting worse” (p. 




couldn’t even find the nipple on my breast” (p. 263).4 Darker skinned women commented 
about their skin getting darker, for example, “dark and ugly, too dark, like toast when it 
burns, black and crispy, burnt, and charcoal” (p. 263).4 Participants in our study and in the 
study by Schnur et  al.4 commented about radiodermatitis causing a greater need to cover 
up during the summer. 
 
Prevention and Management of Radiodermatitis 
 
Nine of the 40 participants mentioned an aspect of preventing or managing 
radiation dermatitis. There were vigilant about inspecting skin in the radiation treatment 
field and applying prescribed creams. 
-The most important issue is keeping my skin healthy and moisturized while in 
treatment. 
- Making sure that my skin improves a little bit each day so that I don’t have 
any open sores or infection. 
A number of women commented about adjusting clothing selection or physically 
altering  clothing to enhance comfort, keep prescribed creams in place and without 
ruining  clothing, and to avoid worsening of moist desquamation caused by clothing 
friction. 
- I think just the right choice of clothes to wear and can make a difference 
of comfort throughout the day. 
- I am wearing my husband’s old tee shirts. I do not want to ruin good clothes! 
 
- I am going to Goodwill today. I am going to buy some old tee shirts. I am 
going to cut the arms off and leave a big hole so that it does not rub the sores 




-One woman commented about applying cream to the radiation site and wearing 
her bra over the camisole to keep the cream in place while she worked. 
Comparably, women in the study by Schnur et al.4 in 2011 commented about having to 
go braless, changing from an underwire bra to one without an underwire, wearing a 
camisole or undershirt; or needing to wear loose clothing, only black bras, or old t-shirts 
because of greasy, oily skin creams.4 Large breasted women discussed inability to go to 
church and family functions such as weddings because they were unable to wear an 
underwire bra.4 
 
Knowledge and Preparation for Radiotherapy 
 
Although each patient is taught by a radiation oncology nurse and radiation 
therapist, some women that experienced the most severe skin toxicity believed radiation 
skin changes were downplayed by the healthcare team. These women thought every 
breast cancer patient that receives radiotherapy develops severe skin toxicity and they 
recommended additional teaching before the start of radiation therapy. 
- There seems to be more concern with how the skin ‘looks’ rather than how 
it ‘feels’ to the individual. Radiation skin changes probably follow a pattern 
on a continuum. I would have liked to have had a visual aid and descriptive 
of some  sort to show that. 
-I feel an important issue is how you are going to feel. The more you know the 
better. Everyone is different and reacts different but if you have a really good 
idea  how your skins going to feel you can be prepared on how to dress and 
your social life. 









The study was an attempt to describe the thoughts and experiences of women at a 
cancer program in a community setting who were experiencing breast radiodermatitis and 
to extend our understanding of quality of life in this population by exploring the rich 
information provided by these women. Twenty-eight participants provided 60 narratives 
from which 36 codes were identified. The codes led to the generation of six themes 
including perspectives on having radiodermatitis, sensations caused by radiodermatitis, 
emotions induced by skin changes, physical appearance of the breast skin, prevention and 
management of radiodermatitis, and knowledge and preparation for radiotherapy. The 
themes suggest that radiodermatitis has a significant impact on quality of life. 
Some of our results closely mirror those of Schnur et al.4-5 The dimensions of 
QOL identified by Schnur et al.4 (e.g., physical discomfort, body image disturbance, 
emotional distress, and impairment of day-to-day functioning) are similar to the DLQI 
subscales (i.e., symptoms & feelings, daily activities, leisure, work & school, personal 
relationship, treatment). We asked participants which DLQI item was most important and 
why. Most of the themes identified in our study relate to DLQI items and subscales. 
The participants in our study wrote about concerns not voiced by the participants 
in the study by Schnur et al.4 For example, our study participants mentioned the sensation 
of boiling inside, the importance of selecting fabric that breathes, and concerns about 
future recurrence. To the authors’ knowledge, this is the first study to mention a sensation 
of boiling inside the breast among breast cancer patients and a preference for clothing 




appearance of the skin.4,12 Similarly, a preference for soft and loose clothing was reported 
in a previous study,4 but did not include natural fabric such as cotton that breathes. While 
not reported by Schnur et al.,4 fear of breast cancer recurrence has been reported in other 
studies13 and therefore is an important consideration when studying quality of life in this 
population. 
 
Strengths and Limitations 
 
This study portrays the perceptions and experiences of women receiving breast 
cancer care in a community setting. To the authors’ knowledge, this is the first study with 
a primary outcome focusing on skin-related quality of life among women experiencing 
breast radiodermatitis in a community setting. It was important to compare our findings 
in a community setting against those of Schnur et al.4 in an urban setting to determine the 
generalizability of both sets of findings. There were many similarities and a few 
differences in these findings. Although our sample represents one community which has 
limited diversity, it may characterize much of the Midwestern U.S. and provide a 
foundation for future studies. 
We conducted a small pilot study to inform larger future studies. Therefore, the 
sample size was modest. Our participants provided insightful responses to the most 
important issue question, but they did so independently which did not allow for 
professionally probes. We can use this information to design a future study that will 






The results of this study provide an important glimpse into the perceptions of 
breast cancer patients who received external radiotherapy in a community setting and 
experienced radiation dermatitis. Each person has a unique view of personal health. Our 
results show a broad range of responses. Several women expressed that radiodermatitis 
had profound impact on their quality of life while others were surprised that radiation 
therapy was easily tolerated as compared to chemotherapy. Two important new findings 
were identified: a boiling sensation within the breast not on the skin surface and a 




Additional studies in community settings across the U.S. are needed to compare 
against our results, including additional cultural and ethnic groups. More studies are 
required to describe of breast radiodermatitis among women with inflammatory breast 
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Table 6.1 Sample Characteristics (n = 28) 
 
Characteristic Range Mean SD 







Non-Hispanic White  27 96.4 
Asian/Pacific Islander  1 3.6 
Level of Education 





High school graduate or GED  5 17.9 
Vocational training after high school  1 7.1 
Some college or associate degree  11 39.3 
College graduate (B.A. or B.S.)  8 28.6 
Master’s degree  1 3.6 
Occupation 
Homemaker or housewife 3 10.7 
Professional specialty or manager 9 32.1 
Technical, retail, administrative 
support, or skilled worker 
9 32.1 
Service 2 7.1 
Laborer 2 7.1 
Other 3 10.7 
Annual Income (range) 
 
Under $15,000 3 10.7 
$15,001-$25,000 1 3.6 
$25,001-$35,000 2 7.1 
$35,001-$45,000 1 3.6 
$45,001-$60,000 4 14.3 
$60,001-$75,000 5 17.9 
Over $75,000 12 42.9 
Cancer Stage   
0 (Tis) 4 14.3 
I 5 17.9 
IIa 10 35.7 
IIb 1 3.6 
IIIa 4 14.3 
IIIb 2 7.1 
IIIc 2 7.1 
Histology   
Ductal 19 67.9 
Lobular 5 17.9 
DCIS 4 14.3 
Grade 
1 3 10.7 
2 13 46.4 
3 12 42.9 
Surgery 
Did not have surgery 1 3.6 
Lumpectomy 18 34.2 
Mastectomy with immediate 
reconstruction 
4 14.3 
Mastectomy without reconstruction 5 17.9 
Chemotherapy before Radiotherapy 
Yes 17 60.7 
 
 









Themes n (%) Codes n 
 
Perspectives on Having 
  Radiodermatitis 13 (22)    Could be worse 2 
Stay positive 2 
Social activities and family are important 1 
Very lucky and fortunate 1 
Happy only had 3 weeks of (dose dense) treatment 1 
Want to move on 1 
A purpose 1 
Difficult to maintain 100% positive 1 
Skin is a constant reminder of cancer experience 1 
Blocking time for radiation therapy 1 
Months behind on my schedule 1 
Sensations Caused by 
  Radiodermatitis 19 (32)    Itching 7 
Tenderness 7 
Boiling inside of my breast 1 
Comfort level is important 1 
Fabric that does not breathe causes claustrophobia 1 
I feel like a grease monkey 1 
Breast expanders cause bother 1 
Emotions Induced by Skin 
  Changes 8 (13)    Depression about breast appearance 2 
Stoicism (hiding emotions) 1 
Fear of radiation therapy 1 
Concern for future recurrence 1 
Eager to recover 1 
Have bigger things to worry about 1 
Pleasantly surprised 1 
Physical Appearance of the 1 









[Like a] mild sunburn 1 
  Radiodermatitis 9 (15)    Choosing or creating the right clothes 4 
Faithful in caring for my skin 2 
Keeping skin healthy and moisturized 2 
Trying to avoid blisters and tearing 1 
Knowledge and Preparation for 
  Radiotherapy 6 (10)    Knowing what to expect 5 
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To explore the relationship between skin-related and global quality of life among 
women experiencing breast radiodermatitis; describe the change in and determine factors 
related to skin-specific and global quality of life (QOL) among women undergoing 




Forty women undergoing whole breast 3-dimensional conformal radiotherapy at a 
community cancer center completed the Dermatology Life Quality Index (DLQI) and 
Quality of Life-Breast Cancer Patient Version at baseline before and at five weeks on 
radiotherapy. Skin toxicity was measured using the Radiation Therapy Oncology Group 
(RTOG) Acute Radiation Morbidity Scoring Criteria-Skin scale. A Kendall’s tau 





In general, skin-related and global quality of life was highly correlated. Skin- 
related QOL changed profoundly (p<.001) while global QOL did not change (p=.55) 




Radiation-induced skin toxicity has a major impact on many subtypes of skin- 
related but not as strongly on global QOL. Additional larger studies in more diverse 






Skin toxicity is a common issue among women receiving radiotherapy for breast 
cancer. The incidence of radiodermatitis of the breast ranges up to 100%.1 Few studies 
have examined the impact of breast radiodermatitis on quality of life as a primary 
outcome. Schnur et al.2 found in their 2009 pilot study that breast cancer patients 
receiving radiotherapy perceived there is a time when symptoms should appear and a 
time when those symptoms should resolve; the patients feared cancer recurrence, 
receiving the wrong treatment, or the symptoms may never end; the patients perceived 
themselves as physically repulsive and felt guilty about not being able to do everything 
they did before the breast cancer diagnosis. In 2011, these researchers followed the pilot 
with a larger study. In this second study, breast cancer patients commented that sunburns 
go away, but radiation burns keep getting worse; they were anxious for their skin’s 
appearance to return to normal; they often needed adapt their clothing and this impacted 
their social activities.3 Wadasadawala et al.4 found similar results in women who received 
whole breast radiotherapy had worsened perception of body image and more financial 
concerns than women who received interstitial multicatheter brachytherapy. 
Knobf and Sun1 found women undergoing radiotherapy for breast cancer reported 
experiencing pain, twinges, skin changes, fatigue, sleep disturbances, and breast edema. 
Comparably, women in the study by Wengström et al.5 described having pain, skin 
changes, and fatigue at the end of breast radiotherapy. All of the participants in Knobf 
and Sun’s1 study experienced a skin change by the fifth week of radiotherapy. Similarly, 
100% of the breast cancer patients in a study by Berthelet et al.6 developed skin toxicity 




receiving external radiotherapy for breast cancer are likely to develop radiodermatitis and 
experience a detrimental effect on their QOL. 
A number of studies focused on testing agents to prevent or manage skin toxicity 
and measure quality of life (QOL) as a secondary outcome. For example, Rollmann et al.7 
investigated the efficacy of emu oil as compared to cottonseed oil to reduce skin toxicity 
and maintain higher levels of skin-related and global QOL. Chan et al.8 also used skin- 
related QOL as a secondary outcome when comparing the use of allantoin versus aqueous 
cream to reduce skin reactions. Hindley9 investigated the value of mometasone furoate 
and diprobase creams to reduce radiation skin reaction of the breast. Participants in the 
mometasone furoate arm enjoyed better skin-related QOL. 
Receiving chemotherapy prior to radiotherapy has a negative impact on QOL 
among breast cancer patients. The European Organisation for Research and Treatment of 
Cancer Quality of Life Questionnaire-30 (EORTC-QLQ-30) is a well-validated 
instrument composed of scaled items.10 The potential total transformed score for the 
EORTC-QLQ-30 ranges from zero to 100, with higher scores representing better QOL.11 
Marino et al.12 measured QOL on the first day of the last cycle of chemotherapy and at 
the end of radiotherapy among women with breast cancer. The median score for global 
QOL in the general population is 75 and role functioning is over 83.3.10 The mean score 
for global QOL was 60.19 in the standard chemotherapy and 59.13 in the high dose 
chemotherapy group on the first day of the last chemotherapy cycle.12 Further, the mean 
score for role functioning was 60.62 in the standard and 35.61 in the high dose 
chemotherapy group at the end of radiotherapy.12 




impacts body image, clothing selection, and ability to engage in activities of daily living. 
Skin-related and global QOL are often used as secondary outcomes in studies designed to 
test the efficacy of agents to prevent or manage radiodermatitis in previous studies. 
Additional studies that explore skin-related and global QOL in the presence of 






The aim of this pilot study was to investigate the impact of breast radiodermatitis 
on skin-related and global quality of life. More specifically, we sought to: 
1. Explore the relationship between skin-related and global quality of life among women 
experiencing breast radiodermatitis. 
2. Measure change in skin-related and global quality of life before the start of and at 





A longitudinal study using repeated measurements was implemented to explore 
the study aims. 
 
Sample and Setting 
 
A purposive sample of 40 women undergoing 3-dimensional conformal 
radiotherapy for breast cancer was recruited. The study was conducted in a single 






Ethical approval was gained from the University of Utah Institution Review 
Board (UIRB), Salt Lake City, Utah, USA. A reliance agreement was created between 
the UIRB and the health care system affiliated with the cancer program. All participants 




RTOG Acute Radiation Morbidity Scoring Criteria-Skin (RTOG score) 
 
The Radiation Therapy Oncology Group (RTOG) score is measured using an 
ordinal scale with a range of 0 to 4. The number represents level of skin toxicity. Zero 
corresponds to “no change from baseline” and level 4 corresponds to “ulceration, 
hemorrhage, necrosis.”13 The RTOG score is used to identify the maximum level of skin 
toxicity in the entire radiation treatment field. It was developed by radiation oncology 
experts in 1985 to complement the existing criteria for late-onset skin toxicity, but has 
not been formally validated.14 
Breast Skin Assessment Form (BSAF) 
 
The BSAF is an investigator-developed tool designed to collect the RTOG skin 
toxicity score for seven areas in the breast radiation treatment field, maximum score, sum 
of the seven scores, cumulative radiation dose, a line drawing of a breast image, 
identification of laterality of breast treated, and comment section. These data were 




Dermatology Life Quality Index (DLQI) 
 
The DLQI is a 10-question instrument that explores the participant’s perception of 
skin condition impact on quality of life. It was designed to minimize survey burden when 
used weekly. Weighted scores range from 0 to 30 with higher scores indicating  
worsening quality of life.16 The independently investigated and reported reliability of the 
DLQI for use among individuals with psoriasis and eczema was a Cronbach’s alpha of 
.83.16 The DLQI was previously used for but formally validated for use in 
radiodermatitis. This instrument was completed by participants in the current study at 
baseline and weekly during radiotherapy. 
 
Quality of Life-Breast Cancer Patient Version (COH-QOL-Breast) 
 
The City of Hope Quality of Life-Breast Cancer Patient Version is an instrument 
consisting of 46 ordinal scale items that measure the participant’s perception of breast 
cancer impact on global health-related quality of life.17 The total score can range from 0 
to 460. Traditional coding of responses on the COH-QOL-Breast leads to a higher score 
indicating better quality of life. The reported overall Cronbach’s alpha for the COH-QOL 
is r =.89 and is r = .81 for the social concerns, r = .88 for the physical well-being, r = .88 
for the psychological well-being, and r = .90 for the spiritual well-being subscales.18 A 




A Kendall’s tau correlation was used to explore the relationship between 
measures of skin-related and global QOL. Responses on the COH-QOL-Breast were 




correlation. Paired t-tests were used to measure the change in skin-related and global 






The 40 adult female participants of this pilot study were undergoing external 
radiation therapy. They were primarily White, middle-aged, nearly obese, previous 
smokers, and likely to experience a sunburn. Eligibility criteria included stage 0-III breast 
cancer but most had had stage IIa or less, grade 2, estrogen and progesterone receptor 
positive, ductal carcinoma treated by lumpectomy and chemotherapy. None of the  
women received concurrent hormone therapy. Additional details are reported in Table 4.1 
(i.e., Chapter 4) of this dissertation. 
 
Relationship Between Skin-related and Global QOL 
 
The DLQI and COH-QOL-Breast were coded so that higher scores indicated 
worsening QOL. All 40 participants responded on the DLQI at five weeks on 
radiotherapy that their skin did not interfere with work or study. Since all participants 
reported their skin did not interfere with work or study, this item could not be correlated 
with other measures. All other components of the DLQI were highly intercorrelated. The 
spiritual well-being subscale of the COH-QOL-Breast was not significantly correlated 
with any component of the DLQI or COH-QOL-Breast instruments. Conversely, 
psychological well-being, the composite score for the COH-QOL-Breast subscales, skin- 
related symptoms and feelings, and composite score for the DLQI were significantly 




measured by the DLQI, skin-related symptoms and feelings, psychological well-being, 
and overall global QOL worsened, all other measurements of QOL significantly declined 
at week five on radiotherapy. See Table 7.2 for additional information. 
 
Changes in Skin-related and Global QOL During Radiotherapy 
 
Paired t-tests were used to measure the difference in skin-related and global QOL 
between baseline and five weeks on radiotherapy. All aspects of skin-related QOL,  
except for attending work and school, significantly worsened between the baseline before 
the start of and five weeks on radiotherapy. Using the mathematical standards for 
interpreting effect size set by Cohen,19 the negative effect on skin-related QOL was  
small, ranging from .06 to .22. See Table 7.3 for additional information. However, using 
the clinical standards set by Basra et al.20 and the DLQI raw scores measured at the fifth 
week on radiotherapy, 30% of the women experienced no effect (raw score 0-1), 40% 
experienced a small effect (2-5), 25% experienced a moderate effect (6-10), 5% 
experienced a very large effect (11-20), and none experienced an extremely large effect 
(21-30). Interestingly, global QOL did not significantly change between baseline and five 
weeks on radiotherapy, suggesting global QOL is more stable than skin-related QOL 
during radiotherapy. Also, a greater amount of impact on QOL is required to cause a 
significant change in a 46-item instrument as compared to one with only 10 items. 
Physical and psychological well-being worsened slightly, while social concerns, spiritual 
well-being, and overall global QOL improved minimally between baseline and week five 






We aimed to describe the impact of breast radiodermatitis on skin-related and 
global quality of life. Skin toxicity did not prevent those participants who were employed 
from working at week five on radiotherapy. This was evident by zero variance during 
statistical analysis for the DLQI work and study subscale among all participants. 
The indicators of spiritual well-being were not significantly related to other 
aspects of skin-related and global QOL in this study. While we do not know the exact 
reason for these null results, they may relate to the fact that spirituality is a subjective 
experience: more important to some participants and less important to others.21 
Conversely, other factors such as physical discomfort may represent symptoms that 
cancer patients experience somewhat in common. 
Worsening overall skin-related QOL and the skin symptoms and feelings subscale 
was significantly associated with a decline in global QOL, physical and psychological 
well-being, and social concerns. Similarly, declining psychological well-being was 
strongly associated with worsened overall skin-related QOL, symptoms and feelings, 
daily and leisure activities, personal relationships, and treatment. However, there was  
only a negligible change in global QOL between baseline and week five on radiotherapy. 
This suggests that some aspects of skin-related QOL such as symptoms (i.e., pain, itching 
burning) have a profound impact on global QOL; while other components of skin-related 
QOL have less impact on global QOL. 
All measures of skin-related QOL significantly worsened between baseline and 
the fifth week of radiotherapy. To our knowledge, this is the first study prospectively 




studies on breast cancer-related quality of life as a primary outcome have focused on 
cancer survivors who have completed treatment, not those actively receiving 
radiotherapy.2,3 A number of studies use QOL as a secondary outcome when comparing 2 
interventions to manage radiodermatitis. However, it is important to study QOL as  a 
primary outcome among patients actively receiving treatment because QOL data can be 
used to predict the onset of cancer treatment-related toxicities.24,25  Additionally, QOL 
data can be used as an endpoint in cancer clinical trials and to guide clinical care as does 
laboratory data.24,25 
We measured the maximum grade of skin toxicity in 7 areas of the breast 
 
treatment field weekly during radiotherapy and summed these scores each week. The 
clinical significance of these summed scores remains to be determined. However, the 
individual toxicity score for site in the treatment field combined with skin-related QOL 
might be useful for testing the efficacy of a radiodermatitis prevention or management 
intervention for that specific treatment site. For example, an agent may work well on the 
surface of a breast quadrant but not in the inframammary fold or vice versa. 
Our pilot study had some limitations. The sample size was modest, included 




Other investigations support the results of our pilot study that breast 
radiodermatitis has a profoundly negative impact on QOL. More specifically, our results 
indicated all aspects of skin-related QOL, except for work and school, significantly 




QOL did not significantly change between baseline and five weeks on radiotherapy. 
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Characteristics of the Dermatology Life Quality Index (DLQI) and City of Hope Quality 
of Life-Breast Cancer Patient (COH QOL-Breast) Instruments 
 
 
DLQI COH QOL-Breast 
Number of items 10 46 
Response scale Ordinal, narrative options Ordinal, numeric scale options 
Recall period Over the last week Previous experience 
Subscales/Domains Symptoms and feelings (2 
items) 
Physical well-being (8 items) 
Daily activities (2 items) Psychological well-being (23 
items) 
Leisure (2 items) Social concerns (9 items) 
Work and school (1 item with 2 
parts) 
Personal relationships (2 items) 
Treatment (1 item) 
Comment One item has two parts. The 
first part is answered yes, no, or 
not relevant. Participants who 
answer “no” are asked to 
respond to the second part of 
the item which has a scaled 
response. 











Intercorrelations among Skin-related and Global Measures of Quality of Life in Women with Breast Cancer at Week 5 on 
Radiotherapy (n = 40) 
 
Skin-related QOL 



























         
 3. Daily 
Activities 
.695** .414** ------         
 4. Leisure 
Time 
.638** .510** .557** ------        
 5. Personal 
Relationships 
.547** .384** .457** .815** ------       
 6. Treatment .660** .525** .452** .348* .350* ------      
Global QOL 7. COH-QOL 
Composite 
.362** .248* .266* .321* .307* .314* ------     
 8. Physical 
Well-Being 
.250* .303* .125 .227 .204 .195 .599** ------    
 9. Psychological 
Well-Being 
381** .269* .308* .394** .355** .333** .804** .501** ------   




































  Well-Being   
** Kendall’s tau correlation is significant at the 0.01 level (2-tailed) 
* Kendall’s tau correlation is significant at the 0.05 level (2-tailed) 
 











Change in Skin-related QOL between Baseline and 5 Weeks on Breast Radiotherapy (n = 40) 
 













Difference 95% CI η2 
  Week 5       
Symptoms & feelings .25 .67 1.50 1.01 -7.16 < .001 -1.25 -1.60 to -0.90 -.22 
Daily activities .13 .46 .93 1.02 -4.97 < .001 -.80 -1.13 to -0.47 -.15 
Leisure .00 .00 .43 .90 -2.98 .005 -.43 -0.71 to -0.14 -.08 
Work & school .00 .00 .00 .00 -------- -------- .00 ------- ------- 
Personal Relationships .03 .16 .28 ,75 -2.04 .05 -.25 -0.68 to -0.00 -.06 
Treatment .00 .00 .63 .03 -4.90 < .001 -.63 -0.88 to -0.37 -.14 
Total .40 1.19 3.88 3.55 -6.32 < .001 -3.48 -4.59 to -2.36 -.19 





Change in Global QOL between Baseline and 5 Weeks on Breast Radiotherapy (n = 40) 
 


















Physical well being 60.03 13.61 60.53 14.13 -.29 .78 -.50 45.59 4.03 to 3.05 
Psychological well being 134.25 44.01 130.75 45.04 .73 .47 3.50 11.11 -6.22 to 13.22 
Social concerns 59.35 18.32 58.28 19.41 .52 .60 1.08 30.38 -3.08 to 5.23 
Spiritual well-being 43.28 13.23 43.00 13.86 .18 .86 .28 13.00 -2.88 to 3.43 
Total 296.90 74.18 292.55 72.23 .60 .55 4.35 9.87 -10.23 to 18.93 
Degrees of freedom (df) = 39 for all analyses 















In this final chapter of the dissertation, a synopsis of the study findings, 
description of limitations and strengths of the study design, recommendations for future 
research, and recommendations for clinical practice are discussed. Then, conclusions 
regarding the study are provided. A synopsis of the participants that took part in each 




We conducted a feasibility and pilot study of the impact of radiodermatitis on 
skin-related and global quality of life (QOL). Our study results may help inform other 
future studies. However, given the pilot nature of this study, caution must be taken 
regarding the application of our results to the care of breast cancer patients. The results of 
our feasibility and pilot study are described in greater detail in Chapter 4 of this 
dissertation. 
 
Feasibility of Study Design and Measures 
 
We carefully examined the pilot study design and measures. Field notes were 
taken throughout the study duration. Recruitment during the radiation oncology 




98%. The refusal rate was 18% with the most common reason for refusal provided being I 
“feel really overwhelmed right now.” 
A few changes are recommended for future studies. We suggest including 
individuals with inflammatory breast cancer who have undergone mastectomy, individuals 
with skin conditions affecting the breast, men, and transgender women. These individuals 
are frequently excluded from study participation. Consequently, we do not                 
know how radiodermatitis differs in these individuals. They can be followed closely 
during studies and reported as a case study if their response differs significantly from the 
other study participants. 
We recommend some changes to our data collection forms. The maximum 
income range collected should be increased beyond $75,000 per year to examine the 
impact of higher income on perceptions and outcomes. A breast skin assessment form 
should be created with an image of a chest wall for use in participants who had a 
mastectomy without immediate reconstruction. Scannable forms would decrease the time 
required to enter data. The forms would still require checking for accuracy by comparing 
the primary source against information in the electronic database. 
Collecting clinician-measured breast length took less than 1 minute and cost 
about $0.15 for each participant. This time requirement and financial cost was deemed 
feasible in our study. Moreover, each study participant agreed to have her breast length 
measured. 
The vast geographic distance between the cancer program and PI’s place of 
employment created a challenge to avoid missing weekly data observations and losing 




onsite with approximately 50% effort dedicated to a study conducted in a community 
setting likely would have shortened the time required to recruit a sample size of 40 
individuals. Measuring skin toxicity by preset cumulative radiation doses might have 




Participant-reported bra cup size and clinician-measured breast length were 
discordant in our study. For example, women reporting a C bra cup size had clinician- 
measured breast lengths ranging from 5.0 to 12.5 centimeters (cms). Similarly, women 
reporting a D bra cup size had measured breast lengths ranging from 7.5 to 10.5 cms. 
This finding is important because in most studies of interventions designed to prevent or 
manage breast radiodermatitis a D cup is categorized as a large breast and a C cup as an 
average-sized breast. Participant-reported bra cup size was an imprecise estimate of the 
actual breast size in our study. 
Increase in breast length significantly correlated with increase in maximum 
RTOG score (p = .04); increased RTOG score in the upper medial breast quadrant (p = 
.04), upper lateral quadrant (p = .02), lower lateral quadrant (p = .02), inframammary fold 
(p = .001); with increasing BMI (p = .002) and bra cup size (p = .0003). Although 
participant-reported bra cup size and clinician-measured breast length were discordant 
breast length and bra cup size were significantly positively correlated (p = .0003). 
 
Multiple Measurements of Skin Toxicity 
 
Assessing skin toxicity grade in seven areas within the radiation treatment field 
was easy to do when recorded on our breast skin assessment form. A one-way within- 




breast using the RTOG scoring system by each individual area in the radiation treatment 
field and the total of all scores at baseline then weekly during radiotherapy. The means, 
standard deviations, Wilk’s Lambda, F statistic, degrees of freedom, significance level, 
and eta squared are presented in Table 4.5 of Chapter 4 in this dissertation. Skin toxicity 
significantly increased with time on radiation treatment in every site within the radiation 
treatment field. There was a significant effect size (η2) for time in each area in the 
treatment field, ranging from η2 = .60 to .89 with the smallest effect in the subclavicular 
 
area and the largest effect in the axilla. The effect of time on the total toxicity score for 
all areas was η2 = .90, p < .001. Every participant experienced a grade 1 or higher skin 
toxicity by week 5 on radiotherapy. We recommend retaining each of the seven 
measurements in the radiation treatment field. Although the subclavicular area was least 
effected, it was a very important assessment for some participants. Also, we recommend 
completing the assessment weekly to allow for comparison of results against other 
scientific studies. 
 
Impact of Radiodermatitis on QOL 
 
Participants completed the Dermatology Life Quality Index (DLQI) instrument 
weekly while receiving external radiotherapy of the female breast. At week 5 on 
treatment, 31 (78%) participants provided narrative feedback on how each DLQI item 
impacted her life. Agreement between the DLQI numerical ratings and the narrative 
feedback was assessed. Agreement between DLQI ratings and narratives ranged from .71 
to .98. Construct validity was estimated using principal component analysis (PCA). The 
DLQI work and study subscale was removed from our analyses because the variance was 




DLQI was assessed using Cronbach’s alpha. The DLQI subscales sans the work and 
study subscale demonstrated good internal consistency, α = .84. 
As overall skin-related QOL as measured by the DLQI, skin-related symptoms 
and feelings, psychological well-being, and overall global QOL as measured by the 
Quality of Life Instrument - Breast Cancer Patient Version (COH-QOL-Breast)  
worsened, nearly all other measurements of QOL significantly declined at week 5 on 
radiotherapy. Skin-related QOL changed profoundly (p<.001) while global QOL changed 
minimally (p=.55) between baseline and 5 weeks on radiotherapy. Lower income was 
significantly related to worsened skin-related QOL (p=.022); while preradiation 
chemotherapy predicted poorer global QOL (p=.01). Maximum skin toxicity predicted 
decreased global QOL (p=.05), but only showed a trend toward decreased skin-related 
QOL (p=.055). 
In addition measuring agreement between participant ratings on the DLQI and 
their narrative feedback on how the construct of the item impacted their life, we asked an 
open-ended question that inquired which DLQI-related issue was most important and 
why. A content analysis was conducted on the narrative responses to the “most 
important” question. The themes identified included perspectives on having 
radiodermatitis, sensations caused by radiodermatitis, knowledge and preparation for 
radiotherapy, prevention of radiodermatitis, emotions induced by skin changes, and 




Our study was limited by a small sample size. For example, we could have 




analysis if we had 460 study participants. The diversity among the participants was 
limited. There was only one woman of color in the study. Men were excluded from 
participation, but their perceptions and risk for radiodermatitis development are important 
too. We focused on woman receiving external radiotherapy, not women receiving intra- 
operative or other partial breast irradiation modalities. Also, a single site in a Midwestern 
community setting was used in our study. While it is important to include cancer 
programs in community settings, our study design would have been stronger if it included 
multiple community cancer programs located in multiple geographic regions of the USA. 
Therefore, the results may not be generalized to the entire population of breast cancer 
patients in the USA. 
We studied women receiving normofractionated or accelerated external 
radiotherapy provided in the supine position using 3-dimensional conformal techniques at 
a community cancer center in northwestern Illinois. Early studies investigating newer 
methodologies such as intensity modulated radiotherapy (IMRT) reported decreased skin 
toxicity as compared to older radiotherapy techniques. Studies by Freedman et al. (2009) 
showed a grade 3 toxicity (i.e., moist desquamation or bleeding from mild trauma; 
National Cancer Institute Cancer Therapy Evaluation Program, 2010) rate of 21% and 
Pignol et al. (2008) reported a grade 3 toxicity frequency of 31.2% in women receiving 
breast IMRT. However, recent studies of radiodermatitis in breast IMRT have 
demonstrated a higher incidence of grade 2 or greater skin toxicity. For example, De 
Langhe et al. (2014) reported a 58% incidence of grade 2 or higher skin toxicity among 
women receiving breast IMRT. Further a study by Pignol, Vu, Mitera, Bosnic, 




among women receiving breast IMRT. These results support the need for skin-related 




We conducted a pilot and feasibility study to inform a future larger study. 
 
Worldwide economic changes have led to reduced funding for research and we need to 
spend our research dollars wisely (Boadi, 2014; National Science Board, National 
Science Foundation, 2008). Pilot and feasibility studies must become the norm before 
larger studies to improve the likelihood of successful completion of larger, expensive 
studies. Also, pilot and feasibility studies need to be highly valued in the realm of grant 
reviews and academia. 
 
Recommendations for Future Research 
 
Greater participation in research by cancer programs in community settings is 
needed to improve the generalizability of cancer research findings. At least 85% of 
cancer patients receive treatment at community cancer programs (National Cancer 
Institute, 2014). Offering access to cancer and genetic research in community settings 
allows the participant to remain in that local setting surrounded by her or his significant 
others and receive continuity of health care from familiar health care providers. The 
National Cancer Institute Community Oncology Research Program (NCORP, 2015) 
provides a partial solution to this issue. However, a majority of cancer programs in 
community settings do not participate in NCORP. In addition, international collaboration 
is needed to include cancer programs in community settings in countries other than the 




We found a florid distribution of radiodermatitis following the line where the 
inframammary fold is normally found in 1 participant who received a mastectomy 
without immediate reconstruction. This suggests the increased incidence and severity of 
radiodermatitis is not exclusively related to friction, traction, or bolus effects of an intact 
pendulous breast, but is potentially related to remodeling that occurs with breast 
development and growth. Additional observations are needed to determine whether this 
phenomenon occurs in other women. The hypothesis might be tested using samples of 
inframammary fold skin from pathology specimens submitted after breast reduction 
surgery. 
Additional studies are needed to test the contribution of genetic and inflammatory 
markers to radiodermatitis. A number of candidate genes and inflammatory markers have 
been identified in vitro and in murine models of radiodermatitis development (Xiao et al., 
2005). The association between some genes and inflammatory with increased 
development of radiodermatitis has been identified in humans. See Table 8.1 and 8.2 for 
additional information on selected genes and inflammatory markers with a known or 
suspected relationship with radiodermatitis. It is estimated that genetic disposition may 
play a role in the development of 80-90% of radiation dermatitis cases (Ho, 2006). 
Additionally, genetic predisposition to radiation dermatitis may indicate tumor sensitivity 
to radiation therapy (Ho, 2006). 
Inflammatory markers may be related prodromal symptoms experienced by the 
patient, but not yet perceived by the clinician. These prodromal symptoms may influence 
quality of life and might therefore be indirectly assessed by measurement of skin-related 




study including measurement of genetic and inflammatory markers possibly related to 
breast radiodermatitis is illustrated in Figure 8.2. 
Predictors of breast radiodermatitis are the focus of a number of studies  (e.g., 
Brown & Rzucidlo, 2011; De Langhe et al., 2014; Hymes et al., 2006; McQuestion, 2011; 
Salvo et al., 2010). Future research looking at predictors of QOL in women with  breast 
cancer is needed. For example, social support may predict skin-related and global  QOL  
in the presence of breast radiodermatitis. “Social support refers to the various types  of 
support (i.e., assistance/help) that people receive from others” (Seeman &  Psychosocial 
Working Group, 2008, para 1). Types of social support include emotional assistance such 
as empathy and reassurance, information intended to provide guidance,  and instrumental 
support involving assistance with physical and financial needs (Cohen,  2004). This social 
support is provided through interactions with one’s social network  (Umberson &  
Montez, 2010). The social network includes significant relationships such  as family, 
friends, and community (Umberson & Montez, 2010). It is important to consider social 
support in breast cancer because it impacts health outcomes (Umberson &  Montez,  
2010). Manning-Walsh (2005) found personal support was positively correlated  to quality 
of life among breast cancer survivors and partially mediated the effects of              
symptom distress. In a study of 3,139 breast cancer survivors, larger social networks were 
associated with higher QOL (Kroenke et al., 2013). 
Additional measures of socioeconomic status (SES) are likely predictors of skin- 
related and global QOL among women experiencing breast radiodermatitis. In our study, 
women with a lower income reported more bother by radiodermatitis. This level of bother 




concerns had a negative impact on global QOL among women receiving whole breast 
radiotherapy. Nutritional status is an important SES factor in wound healing (Marín Caro, 
Laviano, & Pichard, 2007). Dietary factors may play a role in skin toxicity with poorer 
women consuming a less healthy diet. No previous studies exploring this topic where 
found, therefore research is needed in this area. 
 
Recommendations for Clinical Practice 
 
Caution must be taken when generalizing the results of a small pilot and 
feasibility study to clinical practice. Still, a number of women in our study who 
experienced severe radiodermatitis recommended that more emphasis should be placed  
on teaching about the worst case scenario for skin toxicity. They recommended that 
photographs of each possible grade of skin toxicity be included in the teaching plan. One 
participant felt the radiation oncology staff intentionally downplayed how bad 
radiodermatitis really is. She perceived that all women develop moist desquamation. This 
suggests that it might be helpful to include the proportion of breast cancer patients 




A number of preliminary conclusions can be drawn from our pilot study. Our 
piloted measures were feasible. We plan to implement minor changes in our next study. 
We found participant-reported bra cup size and clinician-measured breast length were 
extremely discordant, an important consideration when using breast size as a predictor of 
radiodermatitis. 
Radiation dermatitis had a significant negative effect on skin-related QOL, but not 




used for breast radiodermatitis are promising. However, additional larger studies among 
more diverse populations are needed. 
We estimated the face, content, concurrent, construct validity, and reliability of the 
DLQI among women with breast radiodermatitis in our pilot study. Expert radiation 
oncology nurses approved the content of the DLQI. Agreement between participant ratings 
on the DLQI and narrative feedback on each item was good ranging from 71to            
98%. The variance for the work and study subscale of the DLQI was zero in our study 
population and was automatically removed from the principal component analysis (PCA) 
and Cronbach’s alpha. A PCA was implemented to estimate the construct validity of the 
DLQI. A direct oblimin rotation led to the DLQI subscales loading exclusively on one of 
two components, indicating that each of the remaining subscales should be retained. The 
reliability analysis of the remaining DLQI subscales demonstrated good internal 
consistency with a Cronbach’s alpha of α = .54. Therefore, the DLQI was deemed 
satisfactory for use in our study population. 
The results of our study that focused on the most important item of the DLQI 
provide a glimpse into the perceptions of breast cancer patients who receive external 
radiotherapy in a community setting and experienced radiation dermatitis. Some women 
expressed that radiodermatitis had profound impact on their quality of life while other 
were surprised that radiation therapy was easy compared to chemotherapy. Our findings 
parallel those found in a previous study by Schnur, Ouellette, Dilorenzo, Green, and 
Montgomery (2011) conducted in an urban setting. Our results provide insight into the 
thoughts and needs of women undergoing external radiotherapy of the breast. Individual 




Additional studies focusing specifically on skin-related quality of life are needed. 
 
The results of this study support our original conceptual framework presented in 
Figure 3.1. We hypothesized that whole breast external radiotherapy, physical 
characteristics such as skin phototype and breast size, and lifestyle behaviors including 
smoking and body mass index (BMI) would influence the physical changes that are 
collectively described as radiodermatitis. We further hypothesized that radiodermatitis 
would impact skin-related and global QOL. While some variables demonstrated stronger 
relationships than others, overall, the conceptual framework was congruent with our 
findings. 
Our first next steps include using the data from this study to inform a second pilot 
study that additionally explores the role of genetic and inflammatory markers on the 
development of breast radiodermatitis and changes in skin-related QOL. Additionally, we 
hope to measure light reflectance spectroscopy in the seven areas of the treatment field 
then compare those measurements against clinician-rated skin toxicity in the same areas. 
Eventually, we hope to participate in a large international study of breast radiodermatitis 
using multiple cancer programs. This design would provide sufficient power to accurately 
detect small but significant changes and afford adequate diversity to produce results that 
are more widely generalizable. Identifying the steps and moderators of radiodermatitis 
development may allow the development of effective precision measures to prevent and 
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Publication Date 
 
ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 Isomura, 2008 
ATM ATM serine/threonine kinase Ho, 2006 
GSTP1 glutathione S-transferase pi 1 Ambrosone, 2006 
IL12RB1 interleukin-12 receptor Isomura, 2008 





nitric oxide synthase 3 (endothelial cell) Terazzino, 2012 
 
RAD21 cohesin complex component Ho, 2006 
SOD2 superoxide dismutase 2, mitochondrial Ho, 2006 
TGBF1 transforming growth factor, beta 1 Anscher2010; Ho, 2006 
XRCC1 X-ray repair complementing defective repair in Chinese hamster cells 1 (Homo sapiens) Ho, 2006; Terazzino, 2012 
XRCC3 X-ray repair complementing defective repair in Chinese hamster cells 3 (Homo sapiens) Ho, 2006; Werbrouck, 2009 
XRCC6 
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chemokine (C-C motif) ligand 2 GENE 
chemokine (C-C motif) ligand 4 
Muller, 2011 
Muller, 2011 
CXCL12 chemokine (C-X-C motif) ligand 12 Muller, 2011 
IL-1a IL1A interleukin 1, alpha Zhou, 2001 
IL-1b IL1B interleukin 1, beta Zhou, 2001 
IL-6 IL6 interleukin 6 Zhou, 2001 
TGFß Transforming growth factor beta Okunieff, 2006; Xiao, 2006; 
  Muller, 2007; Anscher, 
  2010 







































Stage IV breast cancer
Inflammatory breast cancer
Paget disease 
Receiving partial breast irradiation 
< 18 years old 
Inflammatory skin condition currently
present on the breast 
Inclusion Criteria 
Stage 0 to III breast cancer 
Invasive ductal or lobular, DCIS histology
Receiving adjuvant EBT 
Status post mastectomy or segmentectomy 
> 18 years old 
50 women were eligible, 9 declined
participation, 41 consented to participate 
Measures 
Original RTOG Scale Completed at: 
BSAF baseline & weekly 
DLQI during radiotherapy 
Breast Length Completed at 
baseline
Completed at 
COH-QOL-Breast baseline & week 5 
 
Radiation Skin Changes Form Completed at week 5 
28 participants provided a
usable response to the “most
important” question 
1 participant withdrew, 40 participants
completed all quantitative study measures 31 participants provided usable













Figure 8.2. Logic model of radiation dermatitis-related quality of life (future study) 
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